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Introduction   1
I. INTRODUCTION 
 
Chronic inflammatory processes occur during onset and development of obesity in 
white adipose tissue (WAT). Activation of endothelial cells was recently shown to 
occur early during initiation of weight gain. This thesis shows regulation of 
inflammatory processes in WAT by platelets. Chronic platelet adhesion was detected 
using intravital microscopy at the endothelium of adipose tissue. This platelet 
adhesion seems to promote recruitment of white blood cells (leukocytes) to adipose 
tissue. Platelet-leukocyte interactions are a well-established phenomenon in various 
inflammatory settings of vascular inflammation.  
In the here described scientific project transgenic mice models with deficient platelet 
adhesion due to altered adhesion receptor expression and impaired platelet 
biogenesis show decrease of white blood cell accumulation in WAT. Reduced 
platelet and leukocyte adhesion provokes a significant increase in body fat. 
Therefore, the results described in this thesis indicate a potential and probably 
crucial role of platelets in chronic inflammatory processes during obesity.  
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II. LITERATURE REVIEW 
 
1. Platelets 
1.1. Definition 
 
The first characterization of platelets dated in the 19th century as small, curious 
beads or grains which accumulate to each other to irregular clusters (19). Today it is 
widely established that platelets play a crucial role in inflammatory reactions, 
immune response (232), atherosclerosis (158) and thrombus formation upon plaque 
rupture (160). Platelets function to stop hemorrhage after tissue trauma or vascular 
injury. Activation and aggregation of platelets are induced after the interaction of 
platelet receptors with matrix proteins. The most important component for this 
interaction is collagen (136), a protein in the various connective tissues, but also the 
serine protease thrombin plays a crucial role. Other components reacting with 
platelets are the von Willebrand factor (vWF) and fibronectin; they are both localized 
especially in the extracellular matrix (ECM).  
 
1.2. Anatomy and function 
 
In their resting form platelets show a diameter of 2-4 µm, circulating in a range of 
150.000 - 400.000 / µl in the bloodstream (207). The anuclear cells derive from 
megakaryocytes in the bone marrow and lack genomic DNA (109), however they 
contain megakaryocyte-derived mRNA for the synthesis of proteins (182). With a 
multitude of functions, in some aspects platelets resemble leukocytes when it comes 
to change of shape or formation of oxygen radicals (156). Platelets have an average 
lifetime of 8-9 days with a daily renewal rate (96) and can emit chemotactic factors 
for monocytes and neutrophil granulocytes (63), moreover they show cytotoxic 
activity against blood parasites (25) and tumor cells (107).  
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1.2.1. Structure and activation 
 
Inactivated platelets show a lens-shaped form (112) with an average surface area of 
8 µm2, however within activation they undergo a shape change with formation of 
pseudopods that represent protrusions of the plasma (echinospherocytes) and the 
surface area increases up to 13 µm2 (Fig. 1) (86). 
 
Figure 1: Human platelet spreading 
A human platelet undergoes a conformational change after activation on surface of fibrinogen (193)  
 
 
The platelet can be divided into four zones, from peripheral to innermost: 
1.2.1.1. Peripheral Zone 
 
The platelet plasma membrane is smooth, however high resolution electron 
microscopy revealed a rugose appearance somehow resembling the surface of the 
brain (105). These folds may provide additional membrane when platelets need to 
stretch on surfaces. Thin sections revealed that the platelet plasma membrane has a 
thicker glycocalyx than other blood cells (187). The lipid bilayer on which the 
glycocalyx rests, is a unit membrane and serves an extremely important role in the 
acceleration of clotting, a process solely found in platelets.  
 
 
Literature Review  4 
The glycocalyx is covered with glycoprotein receptors which are necessary for 
facilitation of platelet adhesion to a damaged surface, to promote platelet 
aggregation and interaction with other cells, to accelerate the process of clotting and 
to trigger full activation of the platelet (59, 111, 118, 213).   
The main glycoprotein receptors involved in hemostasis are the glycoprotein Ib-IX-V 
complex (GPIb-IX) and the integrin αIIbβ3 (GPIIbIIIa). The outside surface of the 
platelet is covered with about 25.000 GPIb-IX receptors and 80.000 GPIIb-IIIa 
receptors (254). 
In the submembrane area a regular system of thin filaments resembling actin 
filaments can be found. These filaments have an important role in the shape change 
and also in the translocation of particles and receptors over the cell surface (277). 
 
1.2.1.2. Sol-gel Zone 
 
In addition to the contractile filament system of the peripheral zone the sol-gel zone 
shows two other filament systems in the platelet cytoplasm. One is the microtubules, 
a cytoskeletal support system. The other is the actomyosin filament system, which is 
involved in internal transformation, shape change and contraction of the hemostatic 
plug and clot-retraction (138). The cytoplasmic actin filament cytoskeleton serves as 
a matrix on which all organelles are maintained separate from each other in the 
resting cell. After activation the cytoplasmic actomyosin cytoskeleton has a unique 
role in the platelet contraction and the spatial reorganization of the organelles (86).  
 
1.2.1.3. Organelle Zone 
 
Within the organelle zone, three major types of organelles can be distinguished, α-
granules, dense bodies (δ-granules) and lysosomes. There are also multivesicular 
bodies, which develop in the megakaryocyte and may serve as some kind of sorting 
station (200).  
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Some small mitochondria in the platelet cytoplasm serve an important role in energy 
metabolism. 
The most numerous of the platelet organelles are the α-granules, with a number 
depending of the size of the platelet as well as the presence of other large structures 
(e.g. glycogen) (97). α-granules contain several growth factors like insulin-like growth 
factor 1, platelet-derived growth factors, platelet factor 4 and other clotting proteins: 
thrombospondin, fibronectin, factor V (263), and von Willebrand factor (186). 
Dense bodies are smaller than the α-granule and fewer in number. They contain 
adenosine diphosphate (ADP), adenosine triphosphate (ATP), calcium, histamine 
and serotonin (178).  
 
1.2.1.4. Membranous Zone 
 
The membranous zone contains surface-connected, open-canalicular systems 
(OCS) as well as the dense tubular system (DTS). The OCS can be seen as an 
extension and invagination of the platelet cell membrane and contains tubules 
building up a canal structure to the cell center (8).  
In this way substances can be transported from the plasma to the cell center or from 
the cell organelles outward. Moreover the tubules contain large amounts of free 
calcium-ions that can be secreted into the cytoplasm to activate the platelet (243). 
 
1.3. Receptors 
 
Platelet receptors trigger the reactivity of platelets with a range of agonists and 
adhesive proteins. Due to the fact that platelets lack a nucleus and therefore cannot 
cope with different situations by protein synthesis (de novo), they need to be 
equipped with a wide range of molecules that are presynthesized with an amount of 
physiological functions and the ability to adapt to new pathological situations.  
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One possibility to do this is by altering their phenotype via receptors present in the 
membrane that get expressed on the platelet surface after activation. This fact 
causes platelets to have the highest molecular mass compared to their relatively 
small size. The major platelet receptors have an important role in hemostasis, which 
is the most import function of platelets, either after platelet activation or after an 
interaction with damaged cell walls. The first platelet receptor involved in a disorder 
has been described nearly 100 years ago (91), in the late 1970s and early 1980s a 
more detailed analysis of platelet receptors was published (11, 52, 188). 
Breakthroughs in the known platelet receptors were the description of collagen in 
1999 (51) and ADP as well as ATP in 2001 (101).  
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2. Leukocytes 
2.1. Definition 
 
Leukocytes or White Blood Cells (WBC) are nucleated cells involved in the innate as 
well as the adaptive immune system to protect the organism against infection and 
invaders. WBCs can be found in the blood, bone marrow, lymphatic organ and other 
tissues of mammals (116). All WBCs develop from a hematopoietic stem cell in the 
bone marrow via hematopoiesis and can be differentiated either by structure 
(granulocytes and agranulocytes) or cell division lineage (myeloid cells or lymphoid 
cells). This follows a further classification into the five main types: Neutrophils, 
eosinophils, basophils, lymphocytes and monocytes (Fig. 2). The human blood 
contains about 4.000 to 10.000 leukocytes / mL. 
 
 
 
 
 
 
 
 
Figure 2: Hematopoiesis 
Lymphoid and myeloid stem cells derive from hematopoietic stem cell. Lymphocytes develop from 
lymphoid stem cells; myeloid stem cells develop into neutrophils, basophils, eosinophils, as well as 
monocytes, platelets and erythrocytes (61) 
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2.2. Neutrophil Granulocytes 
2.2.1. Definition  
 
Neutrophil granulocytes (neutrophils) are the most abundant immune cells and 
belong to the innate immune system. They are rapidly recruited to sites of 
inflammation and infection via chemotaxis where they show defensive attributes as 
well as the expression and release of cytokines (117, 242) that can amplify 
inflammatory reactions by other cell-types. Pathogen defense is performed via direct 
ingestion (phagocytosis) (24, 184), release of soluble anti-microbials (degranulation) 
(40) and the generation of neutrophil extracellular traps (NETs) (31).  
 
2.2.2. Anatomy and function 
 
The term “neutrophil” originated from its staining characteristics on hematoxylin and 
eosin. In contrast to eosinophils that stained bright red and basophils that stained 
dark blue, neutrophils stained a neutral pink color. They show a diameter of about 8 
µm in the blood stream and 12-15 µm in peripheral blood smears (181). The nucleus 
of a neutrophil is multilobed, with the single lobes connected via chromatin. The 
cytoplasm contains spars mitochondria and ribosomes, a small Golgi apparatus, but 
about 200 granules. The rough endoplasmic reticulum is completely absent (276).  
Neutrophils can accumulate rapidly at a site of infection and provide a host-defense 
against invading pathogens. When an invader gets ingested the neutrophil is 
removed via apoptosis, this helps to prevent damage from healthy tissues (99, 133, 
214). Life span of a neutrophil is about 8-12 hours, however the life span can be 
prolonged in cytokine respond. The circulating neutrophils are constantly renewed 
from the bone marrow. 
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2.2.3. Signal transduction 
 
Patrolling neutrophils in the post-capillary venules get information about foreign 
invasion by changes on the surface of the endothelium or by soluble agents that 
were released from the infected tissue. Neutrophils are the first leukocytes to arrive 
at the site of infection or tissue injury. The released factors are able to promote the 
migration of the neutrophil towards the site of inflammation. Factors can be cytokines 
like Tumor necrosis factor α (TNF-α) (229) or Interleukin-6 (IL-6) (23) but also 
various products like N-Formylmethionine-leucyl-phenylalanine (fMLP) derived from 
tissue macrophages (192) or endothelial cells like C-X-C motif chemokine ligand 5 
and ligand 1 (CXCL5, CXCL1) (173, 196, 217). The initial response is adherence of 
the neutrophil to the endothelium of the vasculature followed by transmigration and 
crawling towards a chemotactic gradient (see section 2.2.4). The process of 
migration requires the activation of signaling pathways, cytoskeletal rearrangement 
as well as changes in the cell surface molecules.  
 
2.2.4. The neutrophil adhesion cascade 
 
The recruitment of neutrophils to sites of inflammation is initiated by the release of 
pathogen-associated molecular patterns from invading pathogens (PAMPs) or 
damage-associated molecular patterns released from damaged endothelial cells 
(DAMPs) (16). These signals are recognized by surface and also by intracellular 
receptors, that once activated, can secrete cytokines and chemokines that promote 
the leukocyte migration and trigger the inflammatory response (98) (Fig. 3).  
The first adhesion molecules that get expressed on the surface of the stimulated 
endothelial cells are P- and E-Selectin, expression occurs already after minutes or 
few hours. They can bind to P-Selectin glycoprotein ligand-1 (PSGL-1) and E-
selectin ligand-1 (ESGL-1) present on the neutrophil surface (249). This selectin 
signaling initiates a slow rolling process of the neutrophil, followed by strong 
adhesive contacts.  
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Figure 3: The neutrophil adhesion cascade 
Three steps of the neutrophil adhesion cascade can be differentiated: Rolling, activation and arrest. 
Rolling is mediated by selectins, activation is mediated by integrins and arrest is mediated by 
integrins. Over the years, the adhesion cascade has been enhanced with the steps of capture, slow 
rolling, adhesion strengthening and spreading, intravascular crawling, as well as paracellular and 
transcellular transmigration (145). 
 
 
 
The adhesion is mainly triggered by the activation of neutrophil integrins (LFA-1) by 
chemokines like intracellular adhesion molecule 1 and 2 (ICAM-1, ICAM-2) and 
vascular cell adhesion molecule 1 (VCAM-1) (2, 103). These interactions lead to 
transformational changes of the neutrophil via cytoskeletal rearrangement causing 
luminal crawling of the neutrophil along the endothelium until they reach the site of 
transendothelial cell migration.  
The neutrophil then crosses the endothelium transcellular via ICAM-1 or paracellular 
via platelet endothelial cell adhesion molecule 1 (PECAM-1) (47). The current 
evidence from in vivo and in vitro studies indicates that the paracellular migration is 
more prominent than the transcellullar (90% vs. 10%) (265). After transmigration the 
neutrophils can initiate their movement towards the site of inflammation through 
detecting tracks created by chemokine gradients (84).  
 
Literature Review  11 
3. Transmembrane Receptors  
3.1. Definition 
 
Transmembrane receptors are important proteins for communication between the 
cell and the environment. Extracellular ligands like hormones, cytokines, growth 
factors or neurotransmitters bind to the receptor and mostly trigger a change in the 
conformation of the cell receptor. This conformational change then initiates 
intracellular signal transduction. Many biological pathways are regulated by cell 
surface receptors, for example cell growth, differentiation and proliferation (66, 119, 
231, 261).  
Due to the high importance of these signal transduction pathways, a lot of diseases 
like cancer, neurodegeneration and atherosclerosis are caused by mutations in cell 
surface receptors (46, 208). 
Cell surface receptors can be divided into three classes: G protein-coupled 
receptors, enzyme-linked receptors and ion channel-linked receptors (57).  
 
3.2. Integrins 
 
Integrins are present on most cell types and consist of a heterodimer α- and non-
covalent binded β-subunit (Fig. 4) (26). These subunits are mostly involved in linking 
adhesive molecules to the cytoskeleton and can exist in two affinity states, low and 
high, altered by a cytoplasmic signal. It can be differentiated between three major 
integrin families β1, β2 and β3, which are also important for integrin classification, 
and five different Integrins, α2β1 (collagen receptor), α5β1 (fibronectin), α6β1 
(laminins), αIIbβ3 (fibrinogen and von Willebrand factor) and αvβ3 (vitronectin). 
Required for the integrin binding on ligands is the presence of cations (like Mg2+, 
Ca2+ and Mn2+), increased receptor expression on the cell surface and affinity-
modulation of the extracellular domain (74, 128).  
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Figure 4: Integrin structure. 
Diagram of Integrin α- and β- subunits. In the outer membrane surface the subunits have an adhesive 
glycoprotein that can interact with proteins (RGD) to form a binding site. On the inner cell site the 
Integrin can bind to the cytoskeleton (177). 
 
 
A fast presentation of Integrins on the platelet surface can be achieved via 
interaction and fusion of integrin-rich granules with the cell membrane (87). 
Activation of the integrin receptors is managed through a conformational change, 
induced by binding of agonists, like thrombin and ADP, with the membrane 
receptors. This process is called “inside-out-signaling” (174), whereas direct binding 
of ligands on the integrin and the related conformational change is called “outside-in-
signaling” (Fig. 5) (223). 
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3.2.1. GPIIb/IIIa-Integrin 
 
Platelet aggregation is mediated by a specific receptor, αIIbβ3, found on the surface. It 
is a member of the Integrin family, with a capacity to undergo activation and thereby 
transition from a low-affinity to a high-affinity state for the extracellular ligands (38, 
219). This transformation allows binding to fibrinogen (251) or von Willebrand factor, 
which act as bridging molecules between platelets to form aggregates. Also other 
ligands are recognized, such a vitronectin (169), fibronectin (198) thrombospondin 
(4) and CD40 (3), which help to initiate platelet adhesion to the endothelial matrix 
and platelet aggregation (197).  
 
The key role of platelet aggregation for the GPIIb/IIIa-Integrin was demonstrated 
many years ago, in particular antibody blockage of GPIIb/IIIa led to absence of 
platelet aggregation (54), defined this integrin as a potential target for antithrombotic 
therapy (95). αIIbβ3 is of the β3-subfamily of integrins together with αVβ3. The 
Integrin αIIbβ3 is found on the surface of platelets, basophils, mast cells, 
megakaryocytes and tumor cells (20), αVβ3 can be found on a lot of cell types where 
it influences cell adhesion, migration, angiogenesis and atherosclerosis (33, 37). All 
these ligands have the presence of arginine-glycine-asparatic acid sequence (RGD) 
in common, RGD contains peptides that bind to both of the β3 Integrins. 
 
When platelets are circulating in the blood, αIIbβ3 exists in a resting and low-affinity 
conformation. After the stimulation with an agonist, αIIbβ3 gets transformed to its 
higher affinity state (157). The most prominent agonist is fibrinogen. These 
conformational changes get transmitted across the transmembrane domain and 
change the conformation of the extracellular domain ligand-binding site. This leads to 
a shift from the bent conformation to an extended conformation of the extracellular 
domain that is competent to bind soluble ligands (Fig. 5). This ligand binding 
transmits signals from the receptor into the platelet (outside-in-signaling), which are 
important for platelet responses (147). 
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Figure 5: Pathway for activation of αIIbβ3. 
Inside-out-signaling can be induced by binding to a G-protein-coupled receptor. This initiates signaling 
pathways that lead to cytoplasmic tails of αIIbβ3. Talin and kindling cooperate in this activation process 
by triggering the dissociation of the subunits from the transmembrane complex. This leads to a 
conformational change in the extracellular domain, resulting in a conversion from a resting state to an 
extended conformation that is competent to bind soluble ligands (20, 202). 
 
 
 
The GPIIb/IIIa-Integrin mediates the adhesion of activated platelets on the intact 
endothelium (45, 50, 146, 203); in this way the GPIIb/IIIa-Integrin of platelets binds to 
the endothelial receptor “intracellular adhesion molecule-1” (ICAM-1) via adhesive 
bridging proteins like fibrinogen (22). This adhesion leads to an inflammatory 
reaction in vitro, triggering more adhesive characteristics of the endothelial cells 
(165). Also the von Willebrand factor plays an important role in platelet binding to 
GPIIb/IIIa via the GPIba-receptor (30, 36).  
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3.3. Selectins 
 
Neutrophils are rolling along the endothelial cell surface to migrate from the blood 
vessel into the tissue. This process is mediated by selectins, a family of cell 
adhesion molecules (CAM). There are three known members of the selectin family 
(L-, E- and P-Selectin, the prefixes were chosen according to the cell type where the 
molecules were first identified. L-Selectin is expressed on most types of leukocytes; 
P-selectin in storage granules of platelets and the endothelium and E-selectin is 
expressed on the activated endothelium. They are distributed along the leukocyte-
vascular system and can bind carbohydrate ligands. 
The first selectin described to be important for the entry of neutrophils into inflamed 
tissue was L-selectin based on monoclonal antibody (MAb) inhibition (143). It was 
also shown, that activation and migration of neutrophils accompanied with the down 
regulation of L-selectin and an upregulation of Mac-1, suggesting that L-selectin acts 
before the integrins in the adhesion process (132). It was also shown in vivo that L-
selectin mediates the leukocyte rolling; using a recombinant fusion protein blocked 
the rolling of the leukocyte (144). Over the years many studies have confirmed the 
role of all three selectins in leukocyte rolling and the initiation of leukocyte-
endothelium interactions (70, 190). And also the entry of neutrophils into the tissue 
showed to be mediated by all three selectins (120, 176). 
E-Selectin and P-Selectin are absent from the surface of non-activated endothelial 
cells and are expressed first after an exposure of the endothelial cells to an 
inflammatory stimulus. L-selectin however is constitutively expresses on leukocytes; 
the function is controlled by regulation of the ligand. 
E-Selectin expression is triggered by cytokines, like TNF-α or Interleukin-1β (IL-1β), 
reaching maximum levels of expression on the cell surface 3-4h after the stimulation 
(14).  
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P-Selectin expression is inducible by two different mechanisms. After stimulation 
with histamine or thrombin it can rapidly be mobilized to the cell surface of 
endothelial cells within minutes or even faster within seconds on platelets. It is stored 
in α-granules in platelets as well as Weibel-Palade bodies (WPB) in endothelial cells 
(88, 100). The expression occurs within 5 to 10 minutes after stimulation; 30-60 
minutes later the protein gets already cleared from the cell surface by exocytosis. 
L-Selectin is constitutively expressed on neutrophils as well as most myeloid cells 
and a large subset of lymphocytes (143). In lymphocytes it can be downregulated 
during differentiation, however cell activation of neutrophils and lymphocytes causes 
rapid downregulation of L-Selectin. On neutrophils it gets shedded within 1-5 minutes 
after activation by a variety of activating factors like fMLP or TNF-α (93). 
 
3.4. Interactions between neutrophils and platelets  
 
Like described before, platelets adhere firmly to the inflamed endothelium by the 
GPIIb/IIIa Integrin complex via fibrinogen or von Willebrand factor anchoring. 
Activated platelets release more P-selectin from α-granules than the endothelium, 
causing likely a recruitment of leukocytes to the activated platelets and in this context 
a transmigration of the leukocyte through the endothelium (65, 273). P-Selectin 
mediated platelet-leukocyte complexes can be seen rolling along the endothelium 
after platelet activation and this induces an activation of platelet integrins (75, 83, 
171). Infusion of activated platelets into mice leads to a secretion of WPB and an 
increase in the number of rolling leukocytes (68).  
Other molecular mechanisms responsible of platelet-leukocyte interactions include a 
central role of platelet P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1), its 
counter receptor found on leukocytes. In a signaling cascade, this interaction leads 
to activation of the beta-2 integrin Mac-1 and in a firm adhesion between the two cell 
types. The interaction of P-selectin with PSGL-1 also induces upregulation of 
leukocyte tissue factor and biosynthesis of several cytokines (43). 
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4. Cytokines 
4.1. Definition 
 
The term ‘cytokine’ comes from the Greek and essentially means to put cells in 
motion. Cytokines are peptides involved in intracellular signaling and can act in 
autocrine, paracrine and endocrine way. They are produced by a wide range of cells 
including macrophages, T- and B- lymphocytes, mast cells, fibroblasts, endothelial 
cells and stromal cells and include chemokines, interleukins, interferons and Tumor 
necrosis factor (79). The primary definition of cytokines is peptides released from 
stimulated leukocytes that target other leukocytes; eighteen cytokines have been 
described according to this pattern (‘interleukin-1’ to ‘interleukin-18’) (32).  
However, the term ‘cytokine’ may be misleading, because in the meantime also 
interleukins were described who are produced by non-leukocytes and target non-
leukocytes.  
In contrast to hormones that circulate in nanomolecular concentrations in the blood, 
cytokines circulate only in picomolecular concentrations but can increase up to 1.000 
fold during inflammation or trauma. Every nucleated cell and especially endothelial 
cells and macrophages can secrete cytokines in principle (27). 
Many cytokines play key roles in inflammatory reactions, in particular Interleukin-1 
(IL-1), TNF-α, IL-6, IL-11 and Interleukin-8 (IL-8). IL-1 and TNF-α are extremely 
potent inflammatory molecules and can mediate acute inflammation (67, 194). 
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4.2. TNFα 
 
Tumor necrosis factor α (TNF-α) is an inflammatory cytokine involved in the acute-
phase reaction with the definition to increase or decrease its own plasma 
concentration in response to inflammation. It exists as a trimer (230) and is a product 
of activated macrophages and monocytes, neutrophils, fibroblasts, mast cells, as 
well as T and natural killer cells (1, 13, 89). The role of TNF-α is to regulate immune 
cells via induction of fever, apoptotic cell death and inflammation. In the central 
nervous system TNF-α has regulatory functions on crucial physiological processes 
such as the plasticity of synapses (6), learning and memory, as well as sleep 
functions (5, 12, 135). TNF-α is first synthetized as a transmembrane protein, 
cleaved into a soluble form (sTNF-α).  
 
The soluble form of TNF-α can bind to two surface receptors, TNF receptor 1 and 2 
(TNFR1, TNFR2). TNFR1 signaling results in the activation of different signal 
transduction pathways like nuclear factor-kappa B (NF-κB) and the extracellular 
signal-regulated kinase (ERK). These pathways regulate the expression of genes 
that have anti-apoptotic effects, especially the genes regulated by NF-κB (256). 
 
4.2.1. Blockage of TNF-α 
 
Inhibition of TNF-α can be achieved in two different ways. One possibility is to bind 
directly to TNF-α via monoclonal antibodies. Common drugs are Infliximab 
(Remicade®) (94), adalimumab (Humira®) (28) and certolizumab pegol (Cimzia®) 
(211).  
Another way to inhibit the function of TNF-α is to bind directly to the receptor. A 
circulating receptor fusion protein that functions as a TNF-α ligand is etanercept 
(Enbrel®) (80).  
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4.2.1.1. Infliximab 
 
Infliximab binds directly with a high affinity to the soluble and transmembrane form of 
TNF-α thus neutralizing the biological activity and inhibiting binding of TNF-α with its 
receptors. Infliximab is capable of neutralizing all forms of TNF-α (extracellular-, 
transmembrane- and receptor-bound) (48).  
With a high specificity of TNF- α, Infliximab does not bind to TNF-β, a cytokine 
produced by lymphocytes, mediating a high variety of inflammatory responses (180). 
The medical use of Infliximab demonstrated efficiency in autoimmune diseases, 
including Crohn’s disease (72), ulcerative colitis (209), psoriatic arthritis (125) as well 
as Behçet's disease (218). 
In a mouse model Infliximab showed an anti-inflammatory effect on allergen-induced 
lung inflammation of acute asthma (64) and was able to prevent colitis-associated 
carcinogenesis (131). It is also known that the immunoreactivity of infliximab stored 
at 4° C over a period of 6 weeks remains stable, implying Infliximab to be suitable for 
long-time animal experiments (7). 
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5. Adipose tissue 
5.1. Definition 
 
Already in 1987 adipose tissue (AT) was described as a ‘major site for metabolism of 
hormones’ (228) with production of endocrine factors. The characterization of leptin 
in 1994 established the theory of adipose tissue as an endocrine organ (274). In fact 
adipose tissue is a complex and essential endocrine organ with a high metabolic 
rate, to be more specific, AT produces hormones such as leptin, resistin, estrogen, 
TNF-α (127) and the adipocyte-specific hormone adiponectin (215). AT contains 
adipocytes, connective tissue matrix, nerve tissue, immune cells and the so called 
stromal vascular fraction (SVF), a rich source of preadipocytes, endothelial 
progenitor cells, T cells, B cells, mast cells, mesenchymal stem cells as well as 
adipose tissue macrophages (ATM) (204). All of these components are able to 
respond to afferent signals from the traditional hormone system as well as the 
central nervous system. The main function of adipose tissue is the storage of energy 
in form of lipids as well as the energy release. But also the expression and secretion 
of bioactive peptides, called adipokines, plays a crucial role. These adipokines can 
act in the autocrine and paracrine as well as the endocrine way. These interactive 
network functions determine AT to coordinate a variety of biological processes, such 
as energy metabolism, immune function and neuroendocrine function. 
 
5.2. Adipogenesis 
 
The precursor cells of adipocytes are called preadipocytes, a form of undifferentiated 
fibroblasts that can form adipocytes after stimulation. The process of cell 
differentiation by which preadipocytes become mature adipocytes is called 
adipogenesis (58). Key features of adipogenesis are morphological change, 
expression of lipogenic genes, production of hormones like leptin, resistin, TNF-α, as 
well as growth arrest.  
 
Literature Review  21 
 
The development of mature adipocytes from preadipocytes is a progression of the 
activation of many transcription factors. This sequence is initiated with the activation 
of transcription factors of the activating protein-1 (AP-1) family, continuing with the 
induction and expression of peroxisome proliferator-activated proteins (PPAR), a 
proadipogenic transcription factor. Other transcription factors facilitating the 
maturation of adipocytes are Signal Transducer and Activator of 
Transcription (STATs), sterol response element-binding protein-1 (SREBP-1) and 
members of the CCAAT-enhancer-binding proteins (C/EBPs) (153, 212).  
Mature adipocytes start to expand when the energy intake is higher than the 
expenditure. This process is highly regulated by counter regulator hormones like 
insulin, epinephrine, adrenocorticotropic hormone (ACTH) and glucagon. It is also 
known that mature adipocytes retain the ability to dedifferentiate in vitro into 
fibroblast-like cells, known as dedifferentiated fat cells (DFAT). These cells retain 
proliferative abilities and are able to differentiate into mature adipocytes again (163).  
 
 
5.2.1. Phases of Adipogenesis 
 
Two phases of adipogenesis can be distinguished (See Review: Rosen, 2006 (206)): 
The determination phase is characterized as a stage resulting in the conversion of 
the stem cell to the preadipocytes. The preadipocytes is morphologically identical to 
its precursor cell but has completely lost its ability to differentiate into other cell 
types. 
The terminal differentiation phase describes the stage of the preadipocytes adopting 
the characteristics of a mature adipocyte. The preadipocytes acquire the machinery 
necessary for the transport and synthesis of lipids, insulin action as well as the 
secretion of adipocyte-specific proteins. 
Thus in vitro cell lines are mostly based on preadipocytes that are unable to 
transform into other cell types, the terminal differentiation phase is quite better 
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described and investigated than the determination phase. 
5.3. Adipocyte biology 
 
Adipocytes, also known as fat cells or lipocytes are the main components of adipose 
tissue with a specialization of fat storage as energy (18). It can be distinguished 
between two typed of adipose tissue. White adipose tissue (WAT) and brown 
adipose tissue (BAT). WAT and BAT comprise two types of fat cells. Morphological 
differences between brown and white fat cells can already be observed via electron 
and light microscopy.  
 
5.3.1. White adipose tissue 
 
White adipose tissue consists of spherical cells with an average diameter of 10 mm. 
The size can increase as much as 10-fold, especially in the epididymal fat pads (49).  
The increase in size requires a confined arrangement of the adipocyte cell 
organelles, since they are situated next to a unilocular lipid droplet that occupies a lot 
of the cytosolic space. Also the nucleus is compressed between the plasma 
membrane and the fat lipids most of the time. There is a sparse mitochondria 
distribution in white adipocytes and other cell organelles, like the smooth and rough 
endoplasmic reticulum and the Golgi apparatus. Adipocytes store energy in form of 
nutrient-derived triacylglycerol lipids being the main energy reservoir in mammals 
with the highest energy density of up to 85% of the adipocyte weight consisting of 
lipids. During periods of fasting the triglycerides are released by lipolysis and enter 
the mitochondria of metabolizing cells as free fatty acids to produce ATP (234). In 
addition to fuel storage, white adipose tissue also acts as a thermal isolator, 
protecting other organs from mechanical damage.  
The role of white adipose tissue in obesity has become more important over the last 
years. WAT is now recognized as the main source of hormones involved in energy 
balance regulation, like leptin (154, 195). Also the role of adipokines being involved 
in overall metabolic regulation and the pathologies associated with obesity got more 
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significant (152). 
5.3.2. Brown adipose tissue 
 
Brown adipose tissue consists of brown ellipsoid adipocytes with sizes from 15 to 50 
µm that contain multilocular lipid droplets. All classical cell organelles are present; 
the nucleus has a central position. The most important component of brown 
adipocytes is an abundant distribution of mitochondria and the expression of the 
proton transporter uncoupling protein 1 (UCP1) (39). UCP1 generates heat by non-
shivering thermogenesis, activated by fatty acids, and increases the permeability of 
the inner mitochondrial membrane to allow for a return of protons from the inter-
membrane space back into the mitochondria.  
 
5.3.3. Fat depots 
 
For this work four major fat depots in the mouse are defined. The epididymal fat 
pads are paired gonadal, attached to the epididymis/testes in males and the 
uterus/ovaries in females. The retroperitoneal fat pads are located along the dorsal 
wall of the abdomen and surround the kidney. The inguinal fat pads are found 
anterior to the limbs, directly underneath the skin. The brown fat pads are found 
under the skin between the dorsal crests of the scapulae (155). 
 
5.4. Obesity 
 
Obesity and overweight are defined as abnormal fat accumulation that may impair 
health. The body mass index (BMI) is commonly used to classify obesity and 
overweight in adults and is an index of weight-for-height. It is calculated as the 
weight divided by the square of the height in meters (kg/m2). Overweight is defined 
with a BMI greater than 25, obese is defined with a BMI greater than 30 kg/m2. With 
a dramatic worldwide increase of obesity over the past decades, it has become one 
of the most serious public health problems of our time.  
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In fact the worldwide obesity rate has doubled since 1980 with more than 1.9 billion 
adults (over 18 years old) being overweight in 2014 (39%), 13 % being obese (264).  
Obesity and overweight are furthermore part of the so-called ‘metabolic syndrome’, a 
group of risk factors for heart disease, diabetes mellitus and stroke. Other risk 
factors being classified within the metabolic syndrome next to obesity are insulin 
resistance, impaired glucose tolerance, hypertension and hyperinsulinemia (124).  
 
5.4.1. Obesity and inflammation  
 
In 1993 Hotamisligil reported the first evidence that TNF-α disrupts the insulin-
signaling cascade in adipose tissue (104). In addition, animals lacking macrophage 
chemotactic protein-1 (MCP-1), the receptor for macrophage trafficking, were 
characterized by a decrease in macrophage infiltration into adipose tissue that 
resulted in an insulin resistance (122).  
Nowadays it has become fully accepted that the inflammation associated with 
obesity contributes to insulin resistance. There are many inflammatory mediators 
described including Interleukin-1-β (IL1-β), IL-6, IL-8, Interleukin-10 (IL-10), TNF-α 
and MCP-1. The stromal vascular fraction may also play an important role in the 
development of obesity-associated inflammation as well as insulin resistance; cells 
of the SVF have showed to secrete levels of inflammatory mediators exceeding the 
levels secreted by adipocytes (76).  
There are a number of immune cells present in lean adipose tissue. These cells 
inhibit immune cell activation, characterized by expression of anti-inflammatory 
cytokines IL-4, IL-10 and IL-13 that trigger a T-helper cell 2 (Th2)–type response 
(275). Macrophages in lean adipose tissue are a dominant immune cell population, 
represented by macrophages with an M2-like phenotype. M2 macrophages are 
mostly characterized by their ability to metabolize the repair molecule arginine to 
ornithine, which inhibits the activity of nitric oxide synthase (150), a main player in 
the regulation of inflammation. Macrophages have shown to play a key role in the 
inhibition of immune cell activation in murine fat. A failure of ATM responses results 
Literature Review  25 
in the production of pro-inflammatory cytokines like TNF-α (164, 267).  
Early phases of obesity are characterized by an increase in lipid accumulation per 
adipocyte but also by an increase in the accumulation of pro-inflammatory immune 
cells. Mice are the most common used animal models to study obesity via an 
induction of obesity by feeding the animals a high fat diet (HFD). This diet-induced 
obesity (DIO) triggers an accumulation of neutrophils, macrophages and NK cells 
already within the first weeks of HFD, measured as the production of the proteolytic 
enzyme elastase from neutrophils. Inhibition of neutrophil elastase results in 
enhanced insulin sensitivity, in vivo administration of exogenous elastase reduced 
insulin sensitivity (238).  
One of the key events in the onset of DIO inflammation and insulin resistance seems 
to be the polarization of anti-inflammatory M2-macrophages to inflammatory M1-
macrophages (150). A depletion of macrophages causes an improvement of insulin 
resistance (134). In addition macrophages seem to be the main source of pro-
inflammatory cytokines in diabetic patients (235), suggesting that macrophages are 
one of the crucial factors in the development of AT inflammation.  
Later stages of AT inflammation are characterized by necrotic cell death of 
adipocytes as a result of hypoxia (272). This necrosis results in the release of 
DAMPs that drive macrophages to produce even more pro-inflammatory cytokines. 
As a result, adipocytes are surrounded by rings of pro-inflammatory macrophages 
building “crown-like structures” (260) activating the NF-κB signaling cascade in 
macrophages and converting anti-inflammatory cytokines into pro-inflammatory 
cytokines (140) and producing even more pro-inflammatory cytokines like TNF-α 
(42). TNF-α impairs glucose uptake into adipocytes and inhibits the uptake of free 
fatty acids (FFA) (166), hallmarks of lipid metabolism. In addition TNF-α impairs the 
lipid storage capacity by suppressing the differentiation of new adipocytes from 
precursor cells by preventing the induction of PPARγ and C/EBPα, resulting in an 
inhibition of adipogenesis (41). In addition, production of TNF-α also triggers the NF-
κB pathway resulting in an inhibition of adipose tissue growth (241).  
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III. AIM OF THE STUDY 
 
Chronic inflammatory processes occur during the onset and development of obesity 
in WAT. With nearly 2 billion people being overweight worldwide (in 2014), obesity 
has become one of the most serious public health problems of our time (264). 
Furthermore, obesity and overweight are part of the so-called ‘metabolic syndrome’, 
a group of risk factors for heart disease, diabetes mellitus and stroke. Other risk 
factors are insulin resistance, impaired glucose tolerance, hypertension and 
hyperinsulinemia. Therefore, understanding the cellular mechanisms behind the 
onset and development of obesity is an important factor for a potential future 
treatment.  
With leukocytes being well-established players during obesity development, this 
thesis focuses rather on a potential role for platelets and their potential interaction 
with leukocytes in the pathogenesis of obesity.  
 
Specific aims are: 
- Analyze WAT development in wild type animals as well as animals with 
malfunctioned platelets in vivo 
- Document the adhesion of platelets and leukocytes in lean animals, as well as 
animals receiving high fat diet using intravital microscopy 
- Check for specific chemokine and cytokine expression levels in diverse fat 
tissues 
- Analyze the role of potential cytokines on adipocyte proliferation and 
differentiation in vitro 
- Design a scheme of how the interaction of leukocytes and platelets could 
influence the development of WAT  
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IV. MATERIALS & METHODS 
 
1. Research animals 
 
All experiments in this thesis have been done using mice as research animals. Mice 
are easy available, cost-efficient and have a high reproduction rate. There are 
several genetically strains available which are highly congenic and can easily be 
compared with human biological characteristics. Due to their low size, they are easy 
to handle and therefore ideal when it comes to in-vivo experiments. 
 
1.1. Wild type strain C57BL/6 
 
The inbred mouse strain C57BL/6 was created in 1921 by C.C. Little from a mating 
of Miss Abbie Lathrop at the Bussey Institute for Research in Applied Biology. It is 
the most popular mouse inbreeding strain for animal experiments, also presenting 
the genetically background for many other mouse strains.  
In this thesis the C57BL/6 mice were used for the infliximab treatment as well as the 
genetical background strain for the genetically manipulated GPIIb mice. 
 
1.2. Genetically modified animals 
 
The strain GPIIb-/- is characterized by a genetical defect on the GPIIb-locus. The 
defect suppresses the expression of the platelet-specific GPIIb-IIIa-receptor that 
plays a crucial role in the platelet-adhesion on the endothelium. GPIIb deficient mice 
show Glanzmann’s thrombasthenia, an extremely rare coagulopathy. Due to the 
defective levels of the glycoprotein IIb/IIIa, a receptor for fibrinogen, platelet-
fibrinogen-bridging is impaired, thus bleeding time is significantly prolonged.  
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GPIIb-/- mice have been created by Prof. J. Frampton (University of Oxford, 
Department of Pharmacology, United Kingdom)(73). 
 
1.3. Animal Breeding 
 
Animal breeding took place as a bigamy mating in our own animal facility. One buck 
was put together with two female animals. The animals were separated after a 
certain time, or at the latest when the female animals got pregnant. Pubs were 
separated from their mother animals after an upbringing phase of 4 weeks, male and 
female animals were then kept separately. 
 
1.4. Animal Husbandry 
 
Animal husbandry happened at the Medizinische Klinik und Poliklinik I, Ludwig-
Maximilians-Universität München under SPF conditions (“Specific Pathogen Free”). 
SPF includes closed barrier system with personnel lock, material lock, pass-through 
autoclave and overpressure-ventilation. Cages were renewed every week, after 
washing by 80°C and autoclaving by 120°C.  
Animals were held in IVC-system (individual ventilated cages) polysulfone-cages 
type M III (TECNIPLAST, Germany) with a maximum of 3 female animals per cage, 
male animals were held in individual cages. The cages were opened under 
appropriate transfer-stations. The mice got standard chow (Haltungsfutter V 1536, 
Altromin, Germany) and sterile tap water ad libitum. Food, water and litter were 
autoclaved in the animal husbandry only. The temperature measured 20-23°C with a 
stable air humidity of approximately 60%. The sleep-wake-cycle was set to 12h light 
and 12h dark, controlled by a time switch.  
As an appropriate enrichment the cages were equipped with red plastic-houses 
(TECNIPLAST, Germany), sterile pulp paper and coarsely litter to enhance nest-
building and animal welfare.  
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The SPF-status of the animals was controlled regularly testing Sentinel-animals for 
specific pathogens. 
The entire animal experiments were approved by the government of Upper-Bavaria 
(Regierung von Oberbayern) pursuant to §8 of the German Protection of Animals Act 
(Deutsches Tierschutzgesetz, TierSchG, May 2006) 
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2. Operation Methods 
 
2.1. Anesthesia 
 
Surgeries were initiated using inhalation narcosis with Isoflurane (cp-pharma, 
Germany) and oxygen. Isoflurane was given using an evaporator (3% Isoflurane 
mixture). The usage of Isoflurane helps to reduce stress and the injury risk for the 
animals; therefore the entire surgeries were initiated in this way. Animals were set 
into a narcotic-chamber consisting of plexiglas®, which is easy to clean and sterilize, 
connected to the evaporator. After the inhalation of Isoflurane and the extinct of the 
startle reflexes, animals were taken carefully out of the chamber and then injected 
intraperitoneally (i.p.) with a triple-narcosis to bring them into the surgical tolerance-
stadium. After injection the animals were layed into a shaded paper-box to reduce 
noises and optical stimuli. Operation was started after the interdigital reflex 
extinguished as well. The triple-narcosis consisted of Medetomidin (Dorbene vet 1 
mg/mL, Pfizer GmbH, Germany), Fentanyl (Fentanyl 0.5 mg Rotexmedica GmbH, 
Germany) und Midazolam (Midazolam-hameln 5 mg/mL, Hameln Pharmaceuticals 
GmbH, Germany).  
Medetomidin, a α2-agonist, functions as a sedative-hypnotical analgesic with 
muscle-relaxing and analgesic effects. As side effects it has depressing impact on 
the cardiovascular and the respiratory system.  
Fentanyl is a synthetic generated opioid with a highly efficient pain inhibition. Side 
effects can be psycho-motoric symptoms and depression of the respiratory system. 
Midazolam, a benzodiazepine, has sedative and muscle-relaxing effects. 
For a proper usage of general anesthesia, the three narcotics should always be 
injected together.  
The animals got a mixture of 0.5 mg/kg Medetomidin, 0.05 mg/kg Fentanyl and 5.0 
mg/kg Midazolam, diluted with sterile NaCl (isotonic saline solution, Fresenius, 
Germany) as a total capacity of 0.35 mL. The triple narcosis was injected i.p., 10-20 
min after the injection the animals should reach the surgical tolerance-stadium III2. 
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Pulse and respiratory frequency, as well as the continuous extinction of the 
interdigital reflex were checked in regular intervals. The animals lay on a heating mat 
(Dehner, Germany) to guarantee a homothermic state, oxygen was given via a 
respiratory mask. 
 
2.2. Tail vein injection 
 
The administration of fluorescently labeled dye was done via tail vein injection using 
an appropriate restrainer (Broome HAR- 52-04, Föhr Medical Instruments GmbH, 
Germany), which was cleaned properly after usage to avoid pheromonally-induced 
stress. 
To stimulate dilation of the tail veins it was helpful to warm them via putting a glove 
filled with warm tap water directly on top of the tail for a few seconds. The tail was 
taken on its upper end between middle finger and trigger finger to pond the venous 
blood after disinfection of the puncture with Octeniderm (Schülke & Mayr GmbH, 
Germany).  
The stain was injected over a catheter intravenously (i.v.), consisting of a 10 cm long 
polyethylene tube (Portex, 0,28 mm ID 0,61 mm OD, Smiths Medical International, 
USA) equipped with a cannula (30 G, BD Microlance, Becton Dickinson Labware, 
USA) combined with a 1 mL syringe (B. Braun, Germany). The cannula was inserted 
into the dilated Vena coccygea laterals and afterwards the substance was injected 
evenly. 
 
2.3. Cardiac blood withdrawal  
 
To obtain large amounts of blood for platelet isolation and labeling the mouse was 
anesthetized as described above. After reaching the narcotic state the mouse was 
put on a heating mat in dorsal position and disinfected in the thorax area. The skin 
was severed using a sterile operation-scissor.  
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A 2 mL syringe (B.Braun, Germany) combined with a 30 G cannula was injected 
vertical, diagonal to the hind leg, between the first and the second ridge. Blood was 
taken slowly to prevent pre-activation, 100 µL sodium citrate was provided in the 
syringe to prevent coagulation. 
 
2.4. Platelet isolation and labeling  
 
For platelet labeling approximately 1.5 to 2 mL whole blood was needed, furthermore 
it was crucial that the donor mouse had the same genotype as the recipient mouse. 
Mice should also be age and sex-matched. Whole blood was filled with Tyrodes (pH 
6.5) up to 2 mL total capacity. 
After first centrifugation (20 min, 66 G, brake off, RT) platelet rich plasma (PRP) was 
slowly taken off using a transfer-pipette, transferred into a new FACS-tube, filled up 
with Tyrodes (pH 6.5) up to 4 mL total capacity and labeled using Rhodamine B (2 
mg/mL). After incubation at room temperature (RT) in the dark for 3 min, the blood 
was centrifuged again (10min, 1230 G, brake on). Supernatant was discarded, the 
pellet was resuspended in 4 mL Tyrodes (pH 6.5) and in the next step centrifuged 
(10min, 1230 G, brake on) again. The pellet was resuspended in 250 µL Tyrodes pH 
6.5 and 250 µl Tyrodes pH 7.4. All of the steps were performed carefully to prevent 
platelets form being activated during the isolation process. 100 µL of the Tyrodes-
platelets-mixture were measured using a hematology-analysis-device (ABX Micros 
ES 60, Axonlab, Germany) to obtain the exact platelets count. Afterwards it was 
calculated how much Tyrodes-platelet-mixture was needed to produce a platelet-
suspension with a concentration of 120.000 platelets / µL using an Excel-Sheet 
(Microsoft, USA). The isolated and stained platelets mostly lasted for up to two 
recipient mice. 
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2.5. Neutrophil labeling 
 
The neutrophils were labeled using CD45 antibody (Anti-Mouse, Alexa Fluor ® 488, 
Clone: 30-F11, 0,5 mL@1,0 mg/mL, eBioscience, USA). Alexa Fluor ® 488 has a 
maximum emission of 519 nm after excitation at 488 nm (Fig. 6). 20 µL antibody 
were drawed into a syringe submitted with 180 µL NaCl. To prevent fading of the 
dye, the injection should be done directly before imaging. The antibody was injected 
via tail vein (see 2.2.). 
 
Figure 6: Excitation and emission spectrum of Alexa Fluor ® 488 
Alexa Fluor ® 488 is best excited at 488 nm and emits light with a maximum of 519 nm (BioLegend 
spectral data (17) 
 
2.6. Mouse preparation for intravital fluorescence-microscopy  
 
Preparation of the anesthetized mouse started after reaching the surgical tolerance-
stadium III2. The mice were weighed at first and then laid dorsal on a heating mat 
(IOW-3704, Föhr Medical Instruments GmbH, Germany), the snout was put into an 
oxygen mask, connected to an Isoflurane and oxygen evaporator. The abdominal 
region was shaved (Ermila Magnum Handy, Wahl, Germany), unhaired using 
depilatory cream (Veet, Germany), cleaned and disinfected.  
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Operation was done under a stereo-microscope (Zeiss, Germany); a swan-neck-light 
(Zeiss, Germany) illuminated the operation field in an optimal way.  
Right before the intervention the Rhodamine B labeled platelets from the donor mice 
as well as the CD45 antibody (Anti-Mouse, Alexa Fluor ® 488, Clone: 30-F11, 
eBioscience, USA) were given via tail vein injection. 
 
 
2.7. Surgical operation 
 
Operation of the visceral fat pad started after the mouse reached the surgical 
tolerance stadium III2. After disinfection of the skin the mouse was fixed using 
adhesive tapes (Transpore, Germany). The abdominal skin was carefully grabbed 
using a fine forceps (FST, USA) and a lateral incision was performed cranial with a 
surgical scissor (FST, USA), afterwards the upper skin layer was carefully removed 
from the peritoneum. The skin was then fixed laterally on a foam rubber stage using 
a cannula (30 G, Braun, Germany). To ensure isothermal conditions, the whole 
incision area was kept warm and wet using 37°C warm sodium chloride (Braun, 
Germany), which was retained in a tube-like stage made of foam rubber. A small 
incision was made lateral in the peritoneum to get access to the visceral fat pad. The 
fat pad was grabbed using a wet cotton swap and carefully shifted onto the laterally 
pinned skin. A coverslip placed on the fat pad served as a lens in combination with a 
drop of sodium chloride (Fig. 7).  
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Figure 7: Surgical preparation of the visceral fat pad 
After performing a lateral incision of the abdominal skin the visceral fat pad is slowly shifted outside. 
All of the surgical operation steps are performed under wet and warm conditions to feature a natural 
environment. 
 
 
2.8. Fat pad removal 
 
To get a detailed overview about the weight gain in different fat pads, it was 
important to do a proper fat pad removal. Also the size and weight of the organs 
were measured in this way. The fat pad removal started with the perfusion of the 
mouse with 0.9% NaCl. Therefor the mouse got an inhalation narcosis with 
Isoflurane in the narcotic chamber. After the extinct of the startle reflexes, the mouse 
was slowly taken out of the narcotic chamber and terminated via neck fracture. 
Afterwards the body weight was measured. The mouse was laid dorsal onto a 
polystyrene mat and fixed with adhesive tape. The body was wetted and disinfected 
with Ethanol (70%); a couple of tissues were put underneath for an optimal liquid 
absorption.  
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After an abdominal incision the sternum was opened cranially. The right heart 
ventricle was punctured and the left ventricle was perfused with 20mL sterile saline 
(0.9% NaCl). The skin was incised caudally and the uppermost skin layer was 
dissected carefully from the peritoneum. Afterwards the skin was pinned laterally 
onto the polystyrene mat. The subcutan located lymph nodes were removed 
carefully and discarded. Next the subcutan fat pad was removed; left and right side 
were weighed separately from each other.  
All of the removed fat pads were stored, one part for histologic analysis in 
paraformaldehyde and the other part at -80°C in liquid nitrogen for real-time PCR 
analysis. 
The peritoneum was opened caudally and the peritoneal skin was likewise pinned 
laterally onto the polystyrene mat. The epididymal fat pads were removed; also the 
intraperitoneal located fat at the digestive tract was removed and added to the 
epididymal fat depot.  
The retroperitoneal fat pad was be found directly next to the kidneys and was 
removed equally.  
The mouse was then put ventral onto the mat, the fur was wetted and disinfected 
with Ethanol (70%) again, and the skin located cranially above the scapula was 
sliced. The brown fat pads were found directly subcutaneous between the dorsal 
crests of the scapulae and were removed as well. 
After the fat pad removal it was important to weigh solely the carcass. This meant to 
remove all of the organs out of the peritoneum and the thorax, as well as the removal 
of the skin. The extremities were cut off likewise. The tail was removed and the 
animal was decapitated. Afterwards the pure carcass was weighed.  
The elevated fat pad and animal weights were documented properly (according to 
chapter 3.5.) and then inserted into an Excel sheet. The data of the body weight, the 
individual fat pads as well as the carcass weight were furthermore transferred to 
SigmaPlot (Chapter 3.4.) for graphical and statistical analysis. 
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2.9. Chimera Creation 
 
2.9.1. Isolation of bone marrow cells 
 
For the bone marrow isolation two GPIIb-/- as well as two GPIIb+/+ respectively were 
used. The animals got an inhalation narcosis with Isoflurane in the narcotic chamber. 
After the extinct of the startle reflexes, the mice were taken out of the narcotic 
chamber and terminated via cervicale dislocation. After the mice were terminated the 
extremities were cut off, femur and tibia were dissected and freed from surplus tissue 
using a scalpel. Epiphyses were severed in the area of the metaphysis. The bone 
marrow cavity was rinsed with a brown cannula (26G) using sort buffer, that 
consisted of 1-fold PBS, 2 mM Ethylenediaminetetraacetic acid (EDTA) and 2% fetal 
bovine serum (FBS) through a 70 µm mesh into a new 50 mL Falcon tube. The 
solution was centrifuged for 5 min at 300G, 4°C, acceleration 5, brake 9. The 
supernatant was carefully discarded and the pellet was resuspended in 1 mL 
ammoniumchloride (NH4CL) and afterwards incubated for 5-7 min at 4°C. The 
solution was then filled up with 10-20 mL sort buffer and centrifuged for 5 min at 300 
G, 4°C, acceleration 5, brake 9 again. The cells were resuspended in 1 mL sort 
buffer, diluted 1:10 and the cell count was determined using the counting chamber. 
At least 5 million bone marrow cells should be used per recipient animal. The cells 
were resuspended and later on injected in a maximum of 300 µL NaCl per mouse.  
 
2.9.2. Irradiation process 
 
Two C57BL/6 mice were put into an autoclaved box at a time. Mice were not situated 
in boxes longer than 3 hours due to animal welfare conditions. The recipient animals 
being irradiated had the same genotype and sex as donor mice and were of similar 
age.  
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Irradiation was performed using a radiation-unit Mueller RT-250 (200 kV, 10 mA, 
Thoraeus filter, 1 Gray in 1 min 52 s) with a dosage of 6 Gray per mouse, resulting in 
duration of 11 min 20 sec (Fig. 8). Irradiation was repeated once 12-14 hours later. 
The irradiation process resulted in elimination of bone marrow cells. 
4 h after the second irradiation animals received previously isolated bone marrow 
cells from donor animals via tail vein injection as described above. 5 million bone 
marrow cells per recipient animal, diluted in a maximum of 300 µL NaCl were 
applied. After injection the animals were brought into a specialized chimera 
husbandry room. The animals received acid, autoclaved drinking water (pH 3.1) with 
an addition of an antibiotic for 2 weeks (Cotrimoxazol, 5 mL / L).  
About 12 weeks after the irradiation the animals were ready to be used for the fat 
pad removal (described in chapter 2.8.) and the evaluation of the animal and fat pad 
weights.  
Figure 8: Schematic overview of the chimera creation process 
C57BL/6 mice receive GPIIb wt or GPIIb KO bone marrow cells respectively. After a radiation of 6 
Gray the animals are ready for further experiments after 12 weeks. Figure modified (259) 
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2.10. High Fat Diet Regime 
 
The animal groups were set to seven per genotype. Mice were age and sex-
matched. Animals who were planned to serve as platelet donors in experimental set-
ups with high fat diet regime underwent an identical feeding regime as recipient 
mice. 
For adaption of the gastro-intestinal flora animals received a control diet for one 
week before the experiment. This control diet contained 10% metabolizable energy 
from fat (C1090-10, 4% raw fat content, Altromin, Germany).  
After this one-week initial phase the animals were split into two groups. One group 
received normal chow (Haltungsfutter V 1536, Altromin, Germany) for two more 
weeks, the other group received a high fat diet with 60& of the metabolizable energy 
from fat (C1090-60, 34% rat fat content, Altromin, Germany), also for two more 
weeks. 
Food and water was available ad libitum over the whole experiment duration.  
The animals were weighed twice a week, at the same time of day, to observe the 
weight development as well as the state of health.  
After two weeks mice were prepared for intravital microscopy analysis as described 
in chapter 2.7. and imaged using an epifluorescence microscope. Again the number 
of rolling and adherent WBCs and also the number of transient adherent and firm 
adherent platelets were counted and further evaluated as described in chapter 3.3. 
and the following.  
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3. Intravital epifluorescence video microscopy 
 
Epifluorescence microscopy enabled analysis of cells that were labeled with specific 
fluorescent dyes in in vivo models. The technique was based on the fact that 
fluorophores absorb short-wave stimulation light and emit it as long-wave light. 
Platelets were isolated and stained as described above using Rhodamine B. 
Rhodamine B, a dye from the group of Rhodamine, a Xanthen derivative, had 
already been described in the early 20th century (179). Rhodamine B (Fig. 9) 
reached it maximum absorption between 542 and 554 nm and its emission at a 
maximum of 600 nm in a neutral and aqueous solution (226).  
 
Figure 9: Structural formula of Rhodamine B 
By choosing specific filters the epifluorescence microscope could be set to different spectral-light-
areas, as a result only short-wave light reached the dyed cells. Filter in front of a camera let pass 
solely long-wave light around 600 nm to exclude remaining excitation-light. 
 
 
3.1. Structure of the epifluorescent microscopy 
 
The working area consisted of different parts. One part was the surgery space, which 
guarantees optimal oxygen care of the mice together with a heating mat, the surgical 
instruments and a swan-neck light. The other part was the epifluorescence 
microscope (Olympus BX54WI, Japan) with the illumination system MT20-E 150 W 
xenon arc burner (Olympus, Japan) and a charge-coupled device (CCD) camera 
(ORCA-ER, Hamamatsu Photonics, Japan).  
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The third part was a computer (Fujitsu, Japan) with an analysis software Cell-R 
(Olympus, Japan) and a monitor (Samsung, South Korea). Data was directly stored 
on the computer, a copy was burned onto a DVD for backup. 
 
 
3.2. The epifluorescence microscope 
 
Figure 10: Optical path of the epifluorescence microscope 
The epifluorescence microscope requires a near-monochromatic illumination from the light-source 
only xenon-arc lamps can provide. Light with a special excitation wavelength is focused through the 
objective lens and encounters the specimen. The specimen emits a fluorescence light that gets 
focused to the detector (175) 
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The term “fluorescent” referred to a microscope that uses fluorescence light to 
generate an image. Fluorescent dyes got excited with light of a specified wavelength, 
right before emitting light in another wavelength. Optical filters removed scattered 
light (Fig. 10). The structures that wanted to be analyzed could be stained with 
specific fluorochromes. In this study, neutrophils and platelets (Chapter 2.4. and 2.5.) 
were stained as mentioned above and injected directly via tail vein right before the 
imaging process.  
Only light able to excite the fluorescence dye passed the excitation filter. It was 
important that the excitation filter prevents light of the same wavelength in which the 
fluorescence dye glows from getting through. A dichroic mirror mirrored the 
excitation light to the objective, resulting in a fluorescing specimen. This emitted light 
had a higher wavelength than the excitation light and passed the dichroic mirror 
towards the ocular and the CCD camera. The emission filter was an additional 
barrier to prevent reflected excitation light coming from the specimen from reaching 
the ocular. 
 
3.3. Procedure of the epifluorescence microscopy 
 
After clicking “database”  “administration”  “new database” the database is 
named after the experimental date in the format YYMMDD. The camera was set up: 
“Binning” 2x2 (672x512 pixel), “exposure time”: 30 ms, “brightness adjustment” was 
set to automatic. The laser was set depending on the used fluorochromes: “NIBA” for 
Fluor ® 488 stained neutrophils, “Rhod B” for Rhodamine B stained platelets, 
“Acri/Rho” for the dual view of neutrophils and platelets.  
The epifluorescence microscopy started with a first orientation within the fat pad area 
and the search for large and small vessels through the ocular. After the objective 
was adjusted to an adequate area the software was configured in the same way. The 
fat pad was visualized in a 200x magnification. The camera was set into the live 
mode via and a video could be recorded. 
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3.4. Data evaluation with Microsoft Excel 
 
Neutrophils and platelets per video were counted. The file “IVM-Excel” was opened 
and the mouse and the video were named.  
The following values were inserted into the excel sheet: vessel diameter in µm, 
vessel length in µm, WBC adherent, WBC rolling, platelets adherent and platelets 
transient adherent.  
Excel now calculated the factor to norm the vessel length to 500 µm (500 / vessel 
length) and the vessel radius (0.5 * vessel diameter). Also the half cylinder barrel 
was calculated via (vessel length * π * vessel radius) and this value was also normed 
to 150.000 qm² (150.000 / half cylinder barrel).  
This normed value was used to calculate the number of adherent WBC corrected to 
150.000 µm², rolling WBC corrected to 150.000 µm², adherent platelets corrected to 
150.000 µm², as well as transient adherent platelets corrected to 150.000 µm², via 
multiplying the values of the manually counted cell with this normed half cylinder 
barrel value. These values could be quantified and plotted using SigmaPlot® (Systat, 
Germany).  
 
3.5. Documentation 
 
Whenever an animal was used for an experiment, a proper experimental protocol 
had to be made. This protocol provided information about the genetical background 
of the mouse, the genotype, the date of birth, the sex as well as the weight. Every 
operation step had to be logged. The most important thing was also to mention the 
reference number of the animal experiment proposal (Tierversuchsantrag) over 
which the experiment was reported. It was also of high importance to log the amount 
and time point of narcosis given to the animal during the duration of the procedure. 
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In experiments about the fat pad and organ removal it had further be logged which 
organs and fat pads were removed as well as the specific weight of the different fat 
pads.  
4. In vitro culture of adipocytes 
 
To study the effect of different substances on the development and proliferation of 
adipocytes, it was necessary to switch into an in vitro model additionally to the 
intravital experiments. 
 
4.1. Maturation of preadipocytes 
 
The murine 3T3-L1 preadipocytes were bought from ZenBio, Inc, USA (SP-L1-F, 
3T3-L1 Preadipocytes Cryopreserved, 500.000 cells / vial) and stored in liquid 
nitrogen until usage.  
The 3T3-L1 cell line derived from mouse 3T3 cells is a well-established cell line for 
the research on adipose tissue. The cells show a fibroblast like morphology and can 
differentiate into an adipocyte like phenotype (92).  
For beginning the PM-1-L1 preadipocyte medium was warmed up to 37°C in the 
water bath for around 30 min. The frozen 3T3-L1 cells were heated up for 2 min in 
the water bath as well. 10 mL of the PM-1-L1 medium were put into a 15 mL Falcon 
tube and the 3T3-L1 cells were added. After a centrifugation for 5 min, 265G, brake 
on, the cell pellet was resuspended in 10 mL PM-1-L1 medium and added into a cell 
culture flask. Afterwards, the cell culture flask was put into a humified incubator, 37 
°C, with 5-10% CO2. The medium was changed every 2-3 days until cells reached 
confluency of approximately 70-80%.  
After reaching 70-80% confluency the medium was completely removed from the cell 
culture flask and the flask was washed with 10 mL Ca2+ and Mg2+ free phosphate 
buffered saline (PBS). 2 mL Trypsin heated to 37°C were added into the flask and 
together incubated for 3 min at 37°C. Cells were detached carefully from the base by 
tapping the flask. To stop the Trypsin activity at least the twice the amount of PM-1-
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L1 medium was added. 
 
 
The cell culture flask was rinsed and the medium was transferred into another 50 mL 
Falcon tube. After centrifugation at 265 G for 5 min at RT, with brake, cells were 
resuspended in 2 mL PM-1-L1 medium. In the next step cells were transferred into a 
12-well-plate. Cells were counted with a “Neubauer-Zählkammer” counting chamber, 
20.000 cells were transferred per well. 
 
1.2 mL PM-1-L1 medium were submitted into the wells. The plate was put into the 
incubator for 6-8 days, until the cells reached 100% confluency. Medium was 
changed every 2 days. According to different experiment setups the cells were co-
incubated with different substances during their maturation phase (for details see 
below) 
After the cells were confluent there was an additional incubation time of 48 hours 
without medium change before the initiation of the differentiation phase. 
 
4.2.  Differentiation of preadipocytes into adipocytes 
 
The PM-1-L1 medium was first completely removed and 1.2 mL of DM-2-L1 
differentiation medium added per well. After an incubation of 72h the DM-2-L1 
medium was removed and 1.6 mL of the adipocyte maintenance medium (AM-1-L1) 
added. Medium was changed every 2 to 3 days. After 14 days cells were suitable for 
experiments. 
 
4.3. Sudan III staining  
 
The Sudan III staining is a fat-soluble dye that is used to stain nonpolar substances 
Materials & Methods  46 
(Fig. 11), in this case lipids for a better visualization and the possibility to quantify the 
cell sizes in vitro (106).  
 
Figure 11. Structural formula of Sudan III 
The Sudan III dye has a reddish brown appearance and is used to stain triglycerides, lipids and 
lipoproteins (227) 
 
 
The Sudan III solution was prepared by weighing in 300 mg Sudan III powder with 
100 mL Isopropanol (99%). 15 mL of the Sudan III solution were mixed with 10 mL of 
deionized (DI) H2O and then incubated for 10 min at RT. This solution was stable for 
about 2 hours and was supposed to be filtered directly before usage. 
The adipocyte maintenance medium AM-1-L1 was removed from wells and wells 
were washed with PBS. After the removal of PBS the cells were first fixed with 
Paraformaldehyde (4%) for 60 min at RT. The Paraformaldehyde was then removed 
and the wells were washed with PBS again. Afterwards 1.5 mL Isopropanol (60%) 
were added and incubated for 5 min at RT. Isopropanol was removed, 1.5 mL Sudan 
III solution were added in each well and after incubation for 5 min at RT and removal 
of Sudan III solution cells were washed with 1.5 mL tap water. The cell nuclei were 
stained using 1.5 mL of hematoxylin, incubation for 1 min at RT and rinsed. For 
storage the wells should also be covered with tap water to prevent drying. 
 
4.4. Adipocyte growth evaluation 
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The evaluation was made using a phase contrast microscope (Axiovert, Zeiss, 
Germany). The microscope was set to 20-fold magnification (Objective 1x), phase 
contrast 1, 7.4 V illumination. The software was set to mono, 1300x1030 pixel, 
standard, illumination 20 ms.  
Wells were centered and photographed without magnification. One photo was taken 
per well, saved as JPEG and transferred to a computer for further evaluation with 
ImageJ (National Institutes of Health, USA). 
Data was evaluated and quantified using SigmaPlot. 
 
4.5. Neutrophil Isolation 
 
Within the in vitro experiments adipocytes were co-incubated with 
polymorphonucelar neutrophils (PMN) 
 
4.5.1. Preparation of the Percoll gradient 
 
An isotonic Percoll solution was mixed with 90% Percoll (45 mL) and 10% 10-fold 
PBS (5 mL). This worked best if all the substances were brought to 4 °C before. 
Three different Percoll concentrations were prepared.  
- 72% Percoll (10 mL): 7.2 mL isotonic Percoll + 2.8 mL 1x PBS 
- 64% Percoll (10 mL): 6.4 mL isotonic Percoll + 3.6 mL 1x PBS 
- 52% Percoll (10 mL): 5.2 mL isotonic Percoll + 4.8 mL 1x PBS 
 
 
Afterwards 3 mL of each Percoll concentration were pipetted into a 15 mL Falcon 
tube. The 72% concentration was first, then came the 64% and the 52% 
concentration was added last. The gradient was set on ice afterwards. 
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4.5.2. Preparation of the bone marrow 
 
After neck-dissection on anaesthetized mouse extremities were cut off, femur and 
tibia were dissected and freed from surplus tissue using a scalpel. Epiphyses were 
severed in the area of the metaphysis. The bone marrow cavity was rinsed with a 
brown cannula (26G) using 1-fold PBS through a 40 µm mesh into a new 50 mL 
Falcon tube. The solution was centrifuged for 5 min at 300G, 4°C. The supernatant 
was discarded and the pellet resuspended in 1 mL 1-fold PBS and afterwards 
pipetted onto the previously prepared Percoll gradient.  
 
4.5.3. Isolation of the PMNs 
 
The gradient was centrifuged at 1000G, 30 min, 4°C. After centrifugation two red and 
one white layer within the gradient were visible. The white layer, containing PMNs 
was pipetted into another 50 mL Falcon tube together with 50 mL 1-fold PBS and 
centrifuged again at 300G, 5 min, 4°C. The supernatant was discarded and the pellet 
resuspended in 3 mL 1-fold PBS again. After diluting the solution 1:10 with 1-fold 
PBS, 20 µL were transferred into the “Neubauer Zählkammer” counting chamber and 
evaluated as described in chapter 4.1.  
 
4.6. Co-Incubation of Adipocytes with diverse substances 
 
To examine the effect of diverse substances on the adipocyte proliferation, the cells 
were co-incubated on different days during their maturation and differentiation phase 
for 24 h each as described below. 
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4.6.1. Co-incubation with stimulated platelets 
 
Platelets were isolated from donor mice as described in chapter 2.4. and counted. 
The platelet solution was diluted 1:10 using Tyrodes buffer and activated with ADP 
(5 µM stock solution, 9 µL / mL platelet solution) for 5 min at RT. Per well a total 
count of 2 * 106 / mL platelets was added, resulting in a concentration of 1.2 mL (2.4 
* 106), platelets diluted in 200 µL tyrodes buffer. The adipocytes were co-incubated 
with platelets for 24 h and the medium was renewed afterwards. The following 
protocol was used for the co-incubation studies: 
Differentiation day 1: 
- Addition of 1 mL DM-2-L1 medium 
- Incubation for 24h 
Differentiation day 2: 
- Addition of the calculated platelet amount 
- Incubation for 24h 
- Removal of platelets and medium 
- Renewal of DM-2-L1 medium 
Differentiation day 3: 
- Incubation for 24h 
Maturation day 8: 
- Addition of the calculated platelet amount 
- Incubation for 24h  
- Removal of platelets and medium 
- Renewal of AM-1-L1 medium 
Maturation day 14: 
- Addition of the calculated platelet amount 
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- Incubation for 24h 
- Removal of platelets and medium 
- Renewal of AM-1-L1 
4.6.2. Co-incubation with stimulated platelet supernatant 
 
The platelets were isolated from donor mice as described in chapter 2.4. and 
counted. The platelet solution was set to 100.000 platelets / mL and resuspended in 
1 mL tyrodes buffer pH 6.5 and 1 mL tyrodes buffer pH 7.4. The solution was 
activated with ADP (5 µM stock solution, 9 µL / mL platelet solution) for 5 min at RT 
and centrifuged at 1230G for 10 min. The supernatant was then added to the 
adipocytes according to the following protocol: 
 
Differentiation day 1: 
- Addition of 1 mL DM-2-L1 medium 
- Incubation for 24h 
Differentiation day 2: 
- Addition of the calculated supernatant amount 
- Incubation for 24h 
- Removal of supernatant and medium 
- Renewal of DM-2-L1 medium 
Differentiation day 3: 
- Incubation for 24h 
Maturation day 8: 
- Addition of the calculated supernatant amount 
- Incubation for 24h  
- Removal of supernatant and medium 
- Renewal of AM-1-L1 medium 
Maturation day 14: 
Materials & Methods  51 
- Addition of the calculated supernatant amount 
- Incubation for 24h 
- Removal of supernatant and medium 
- Renewal of AM-1-L1 
4.6.3. Co-incubation with stimulated neutrophils 
 
PMNs were isolated from donor mice as described in chapter 4.5.3. and counted 
using the counting chamber. The neutrophil solution was diluted 1:10 using PBS and 
activated with phorbol myristate acetate (PMA) (Calbiochem, Merck Millipore, 
Germany, 20 ng/ mL neutrophils) for 5 min at RT. Per well a total count of 2 * 105 / 
mL neutrophils was added, resulting in an end concentration of 1.2 mL (2.4 * 105), 
neutrophils diluted in 200 µL PBS. The adipocytes were co-incubated with the 
neutrophils for 24 h and the medium was renewed afterwards. The following protocol 
was used for the co-incubation studies: 
 
Differentiation day 1: 
- Addition of 1 mL DM-2-L1 medium 
- Incubation for 24h 
Differentiation day 2: 
- Addition of the calculated neutrophil amount 
- Incubation for 24h 
- Removal of neutrophils and medium 
- Renewal of DM-2-L1 medium 
Differentiation day 3: 
- Incubation for 24h 
Maturation day 8: 
- Addition of the calculated neutrophil amount 
- Incubation for 24h  
- Removal of neutrophils and medium 
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- Renewal of AM-1-L1 medium 
 
 
 
Maturation day 14: 
- Addition of the calculated neutrophil amount 
- Incubation for 24h 
- Removal of neutrophils and medium 
- Renewal of AM-1-L1 
 
 
4.6.4. Co-incubation with unstimulated neutrophils 
 
The neutrophils were isolated from donor mice as described in chapter 4.5.3. and 
counted using the counting chamber. The neutrophil solution was diluted 1:10 using 
PBS. Per well a total count of 2 * 105 / mL neutrophils was added, resulting in an end 
concentration of 1.2 mL (2.4 * 105), neutrophils diluted in 200 µL PBS. The 
adipocytes were co-incubated with the neutrophils for 24 h and the medium was 
renewed afterwards. The time protocol was identical to chapter 4.6.3.. 
 
 
4.6.5. Co-incubation with unstimulated neutrophils and stimulated platelets 
 
The neutrophils were isolated from donor mice as described in chapter 4.5.3., 
platelet isolation followed the protocol in chapter 2.4., platelets were counted using 
the counting chamber. The neutrophil solution was diluted 1:10 using PBS and 
added to the activated platelets diluted in tyrodes. Per well a total count of 2 * 105 / 
mL neutrophils and 2* 106 / mL platelets were added. The adipocytes were co-
incubated with the neutrophils and platelets for 24 h and the medium was renewed 
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afterwards. To improve the cellular environment for the combination of platelets and 
neutrophils Ca2+ (100 mM) and MG2+ (100 mM) were added to the tyrodes buffer 
beforehand. 
 
 
 
Differentiation day 1: 
- Addition of 1 mL DM-2-L1 medium 
- Incubation for 24h 
Differentiation day 2: 
- Addition of neutrophils and platelets 
- Incubation for 24h 
- Removal of neutrophils, platelets and medium 
- Renewal of DM-2-L1 medium 
Differentiation day 3: 
- Incubation for 24h 
Maturation day 8: 
- Addition of neutrophils and platelets 
- Incubation for 24h 
- Removal of neutrophils, platelets and medium 
- Renewal of AM-1-L1 medium 
Maturation day 14: 
- Addition of neutrophils and platelets 
- Incubation for 24h 
- Removal of neutrophils, platelets and medium 
 
4.6.6. Co-incubation with TNF-α  
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Another group of adipocytes was co-incubated with recombinant murine TNF-α 
(ImmunoTools, Germany), 10 ng / mL as well as 1 ng / mL respectively. The TNF-α 
stock solution was 100 µg dissolved in 1 mL sterile H2O, diluted 1:100 to produce 72 
ng as well as 7.2 ng in 200 µL sterile H2O, resulting in an end concentration of 10 ng 
as well as 1 ng dissolved in 1200 µL. 
 
Differentiation day 1: 
- Addition of 1 mL DM-2-L1 medium 
- Incubation for 24h 
Differentiation day 2: 
- Addition of TNF-α 
- Incubation for 24h 
- Removal of TNF-α and medium 
- Renewal of DM-2-L1 medium 
Differentiation day 3: 
- Incubation for 24h 
Maturation day 8: 
- Addition of TNF-α 
- Incubation for 24h 
- Removal of TNF-α and medium 
- Renewal of AM-1-L1 medium 
Maturation day 14: 
- Addition of TNF-α 
- Incubation for 24h 
- Removal of TNF-α and medium  
- Renewal of AM-1-L1 
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4.6.7. Co-incubation with ADP 
 
Adipocytes were also co-incubated with ADP to examine if this stimulus alone 
already has an effect on the adipocyte proliferation. The ADP was added in the same 
concentration as described in chapter 4.6.1., dissolved in tyrodes, also the co-
incubation protocol was identical to chapter 4.6.1.. 
 
4.6.8. Co-incubation with PMA 
 
Adipocytes were also co-incubated with PMA to examine if this stimulus alone 
already has an effect on the adipocyte proliferation. PMA was added in the same 
concentration as described in chapter 4.6.3., dissolved in PBS, also the co-
incubation protocol was identical to chapter 4.6.3.. 
 
4.6.9. Co-incubation with Tyrodes 
 
The cells were co-incubated solely with tyrodes as a control group to check whether 
the cell cultural work steps influence the adipocyte proliferation. 200 µL tyrodes pH 
7.0 were added per well. The time-protocol was identical to chapter 4.6.1..  
 
4.7. Adipocyte preparation for ELISA quantification 
 
To check for the expression of the cytokine TNF-α, the adipocytes were co-incubated 
comparatively to chapter 4.6., but in this setting, co-incubation took place after 
adipocytes were completely maturated at day 18 and incubation time was reduced to 
a time of 3 hours. The ELISA process can be looked up more precisely in chapter 
5.1. 
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5. Infliximab Setting 
 
The mice were treated with Infliximab® (MSD, Germany), a monoclonal antibody 
against tumor necrosis factor alpha for 6 weeks. Afterwards the TNF-α expression 
was measured using a suitable ELISA Kit. 
60-70 day old C57BL/6 mice received an intraperitoneal administration of 6.25mg/kg 
Infliximab® or vehicle (aqua ad iniectabilia) intraperitoneally. Animals were treated 
once a week over 6 weeks. Body weight was measured once a week, directly before 
the treatment. After 6 weeks, mice were anesthetized and fat pads were removed as 
described above.  
Blood serum was collected and TNF-α serum concentrations were determined using 
ELISA according to manufacturers’ instructions (R&D Systems, USA).  
 
5.1. ELISA quantification 
 
For the quantification of the TNF- α concentrations in the blood serum and the in 
vitro supernatant enzyme linked immunosorbent assays (ELISA) were used. The 
ELISA Kit was used according to manufacturer’s instruction (R&D Systems). 
After Infliximab treatment blood was collected via cardiac blood withdrawal and 
serum was centrifuged at 300G, 15 min, 4°C. 
In case of cell culture experiments supernatant was taken, centrifuged (300G, 15 
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min, 4°C) and subjected to ELISA analysis. 
 
5.1.1. Performance of the ELISA 
 
The samples were stored at -80°C at brought to RT before usage. The samples and 
the standard series were used as a dual approach. 
 
For the standard series the Mouse TNF-α Standard was first reconstituted with 
deionized water to produce a stock solution of 7000 pg/mL. After adding 900 µL of 
the calibrator diluent (RD5K for cell culture supernatant, RD6-12 for serum samples) 
to a 700 pg/mL tube, 200 µL of the appropriate Calibrator diluent were added into the 
remaining tubes. The stock solution was used to produce a dilution series (Fig. 12). 
 
Figure 12: Production of the standard series 
The TNF-α Standard was reconstituted with deionized water and was then used to produce the 
standard series. At first 100 µL were added into the 700 pg/mL tube. Afterwards 200 µL were 
transferred into the next tube and so on.  
 
The appropriate Calibrator diluent served as the zero standard and the 700 pg/mL as 
the high standard. From each sample as well as the standard series 50 µL were 
pipetted into the 96 well ELISA plate. The plate was covered and incubated at RT for 
2h on an ELISA plate shaker (Heidolph Duomax 1030, Heidolph Instruments, 
Germany). After the incubation the wells were emptied completely and washed using 
250 µL wash buffer (20 mL wash buffer concentrate were mixed with 500 mL 
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deionized water before). The wash procedure was performed 5 times. Afterwards 
100 µL Mouse TNF-α Conjugate were added to each well and incubated at RT for 2h 
again. The wash steps were repeated as described above. 100 µL of the Substrate 
solution were added to each well and the plate was incubated dark at RT for 30 min. 
Afterwards 100 µL of the Stop solution was added directly into each well. 
 
 
 
5.1.2. ELISA data evaluation 
 
Directly after the stop solution was added the chemical reaction was measured using 
an ELISA plate reader (Infinite F200, Tecan Deutschland GmbH, Germany). The 
software icontrol 1.9 (Tecan Austria GmbH, Austria) then measured the absorption of 
the colored wells. The data was prepared as an Excel sheet and further evaluated 
using an online software tool (myassays.com). The tool calculated the concentration 
of TNF-α per well in ng/mL. The different groups were then compared and 
statistically evaluated using SigmaPlot. 
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6. Analysis of Fat pad vascularization  
 
6.1. Principle of the two-photon microscopy 
 
Two-photon microscopy was used to determine the vascularization level in fat pads 
of whole mount specimen of GPIIb-KO mice and controls. It was an imaging 
technique that was able to perform fluorescent imaging in the living tissue up to 100 
µm in depth. In this way it was possible to perform a three-dimensional in vivo 
analysis in different kinds of tissues over a certain time period (62). Maria Göppert-
Mayer established the theoretical basis of the excitation of two photons in 1931 and 
this photo-physical effect was further verified experimentally in 1963 by Kaiser and 
Garret (121).  
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Figure 13: Jablonski diagram for one-photon (a) and two-photon (b) excitation.  
Two photons arrive simultaneously within a few femto-seconds and excite the electrons of the 
fluorochromes. The femto-second laser source provides sufficient intensity for two-photon absorption 
within a single pulse but is still low enough to avoid damage of the specimen (137, 233). 
 
 
In the excitation process a fluorophore was excited by a simultaneous absorption of 
two infrared photons (Fig. 13).  
 
The one-photon microscope involved the excitation of a fluorophore by a single 
photon, typically in the ultraviolet spectra range. The simultaneous absorption of two 
less energetic photons could generate the same excitation process if the sum of the 
energies of two photons was greater than the energy gap between ground state and 
excited state of the molecule. 
 
6.2. Structure of the two-photon microscope 
 
The two-photon microscope (TrimScope, LaVision BioTec, USA) was composed of a 
titanium-sapphire laser (MaiTai, Spectra Physics, Germany) with a wavelength range 
from 700-1000 nm. An optical-parametric oscillator (OPO) enhanced the excitation 
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wavelength to 1100-1600 nm and increased the imaging depth with a higher 
resolution. The dichroic mirror reflected the excitation light to the objective and 
towards the specimen. Fluorescence was created and raster scanning in three 
dimensions (x-y-z) constructed an image. Afterwards the same objective collected 
the emission signal and transmitted it through the dichroic mirror along the emission 
path.    
 
6.3. Whole mount staining 
 
6.3.1. Injection of the primary antibody 
 
To evaluate the vessel structure of fat pads in GPIIb +/+ and GPIIb -/- mice a CD144 
primary antibody was injected via tail vein to stain the vascular endothelial Cadherin 
(20 µL, Anti-Mouse, Clone: eBioBV13, 20 µg, eBioscience, USA), diluted in 180 µL 
NaCl 0.9%. After 1h incubation transcardial perfusion was performed to reach 
bloodlessness. The method of tail vein injection and transcardial perfusion were 
described in more detail in chapter 2.2. and 2.8.  
 
 
6.3.2. Secondary antibody staining  
 
For whole mount staining subcutaneous fat pads were removed as described in 
chapter 2.8. and transferred into a 1.5 mL Eppendorf tube and fixated with 
paraformaldehyde (4%) for 30 min in the dark at RT. After washing with PBS the 
secondary antibody was added. The secondary antibody was diluted 1:100 in a 1.5 
mL Eppendorf tube. Therefor 500 µL PBS were mixed with 5 µL Alexa Fluor ® 594 
(donkey anti Rat IgG, 2 mg/mL, Thermo Fisher Scientific, USA). The fat pad was 
added and incubated for 1 hour in the dark at RT and afterwards washed with PBS. 
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6.3.3. Fat pad imaging using 2-photon microscopy 
 
Right before the imaging process fat pads were washed with PBS again to remove 
possible unbound antibodies. Fat pads were fixed onto a histology-case filled with 
modeling clay using cannulas and immediately covered with 0.9% NaCl to prevent it 
from drying. The whole mount was put under the 2-photon microscope (LaVision, 
Biotech, Germany) and Imspector software (LaVision, Germany) set to: 
- 3D-Scan 
- Laser: Wavelength 820 µm 
- Size: 558x558 
- Pixel: 837x837 
- Step Size: 2 µm 
- Frequency: 800 
- Line Average: 2 µm 
- Channel: Red, green, blue 
The range was set to 100 µm using the Cell-R software. Per fat pad a total of 6-8 
videos in different areas were recorded. 
 
 
6.3.4. Data evaluation with IMARIS 
 
The two-photon scans were analyzed using IMARIS imaging software (Bitplane, 
Switzerland).  
After analysis a spreadsheet was opened showing different parameters (Area, 
Volume, X-Position). This spreadsheet was “saved as” an Excel file and opened in a 
separate Excel window. The ratio between total fat pad volume and the vessel 
volume (Surface) per fat pad was evaluated as percentage. The ratio values of all 
videos taken from one fat pad were averaged and statistically and graphically 
evaluated using SigmaPlot.  
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7. Statistical Analysis 
 
Statistical analysis was performed using SigmaPlot 12.5 ® (Systat Software Inc., 
Germany). Results with a p-value smaller than 0.05 were considered as statistically 
significant.  Before testing for statistical significance SigmaPlot ® proofed the data for 
being normally distributed using the Shapiro-Wilk-test. After passing the normal 
distribution test data was compared between the wild type group and the Knockout 
animals in the in vivo settings, the untreated with the treated cells for the in vitro 
setting, as well as the untreated with the treated group in the infliximab setting. In 
each case the Student’s t-test was used. If the data did not pass the test for normal 
distribution the Mann-Whitney U test was used. 
For using the statistical tests mean values of each groups were counted and 
compared. Also the standard error of the mean was calculated using SigmaPlot ®. 
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Mean values and standard errors were presented using bar charts. For some 
experiments dot-plots were used for better overview. Here the mean value and the 
standard error of the mean were indicated in the text. 
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V. RESULTS 
 
The thesis addresses the role of platelets and leukocytes in adipose tissue 
vasculature. Therefore, it was analyzed whether platelets interact with activated 
endothelium of adipose tissue vessels. In vivo microscopy was performed in wild 
type versus GPIIb deficient mice. It was further tested, whether platelet adhesion 
assisted leukocyte recruitment and status of adipose tissue mice.  
 
1. Platelet and leukocyte adhesion in visceral WAT 
 
In the here described scientific project the role of platelet adhesion and the 
recruitment of WBC during the initiation of adipose tissue inflammation is evaluated. 
In the first part of the project, performed by PhD-Student Tristan Konrad, platelet 
dynamics in subcutaneous fat depot microcirculation were evaluated. Therefore 8-
10-week old lean αIIb-deficient mice, which lack αIIbβ3-surface expression, as well as 
wild type control animals were used. Using in vivo microscopy, T. Konrad found 
constant low grade platelet adhesion in the microcirculation of subcutaneous tissue, 
which was abolished in the αIIbβ3-deficient mice. Lack of platelet adhesion culminated 
in increased body fat in αIIbβ3-deficient mice. Additionally, Alexa Fluor ® 488 labeled 
CD45 antibody was infused to visualize leukocyte dynamics in subcutaneous 
adipose tissue vessels of lean, wild type or αIIbβ3-deficient 8-10 week old mice. T. 
Konrad found only rare firm leukocyte adhesion. No significant differences between 
leukocyte adhesion in animal groups was found, though data show a tendency in 
reduced leukocyte adhesion in αIIbβ3-deficient mice compared to controls 
(unpublished data). In the pathogenesis of obesity current data described more 
prominent inflammatory processes and WBC actions in visceral compared to 
subcutaneous WAT (35, 77). In a consecutive part of the project I thus analyzed 
platelet and leukocyte dynamics in the visceral WAT of lean 8-10 week old αIIbβ3-
deficient mice and controls.  
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In the first part of the project epifluorescent in vivo microscopy was performed to 
study platelet and CD45+ WBC dynamics in the microcirculation of visceral white 
adipose tissue of lean wild type and αIIbβ3-deficient mice. Fluorescently labeled 
platelets and Alexa Fluor ® 488 labeled CD45 antibody were administered to wild 
type or αIIb-deficient 8-10 week old mice and platelet and WBC adhesion analyzed. 
Transient and firm adherent platelets were mitigated in αIIb-deficient mice (transient 
adherent platelets: p-value 0.013, n = 6, 57.62 ± 11.62 vs. 16.88 ± 7.01, firm 
adherent platelets: p-value 0.009, n = 6, 28.19 ± 7.59 vs. 3.08 ± 1.97) (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
Figure 14: Number of transient and firm adherent platelets 
Platelet adhesion in visceral WAT vasculature was evaluated in GPIIb deficient mice versus wild type 
control. The number of transient adherent as well as firm adherent platelets is reduced in the GPIIb 
deficient mice versus controls (p-value 0.01 and 0.009) 
 
Platelets adhered to visceral fat pad endothelium in lean GPIIb wild type mice (Fig. 
15). This effect was almost abolished in the GPIIb Knockout mice, platelets passed 
through the vasculature without firm or transient adhering to the endothelium. 
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Figure 15: Rhodamine B labeled platelets in GPIIb wild type and Knockout mice 
Representative freeze images of in vivo microscopy of visceral fat pad vasculature shows firm 
frequent platelet adhesion in GPIIb +/+ animals (white arrows) that is virtually abolished in GPIIb -/- 
mice. 
 
Unlike in platelet adhesion dynamics number of rolling WBC remained stable in 
GPIIb deficient mice (p-value 0.562, n = 6, 151.701 ± 19.62 vs. 133.47 ± 23.18) and 
reduced firm leukocyte adhesion in αIIb-deficient mice was found though this effect 
did not reach statistical significance (p-value 0.180, n = 6, 56.98 ± 14.19 vs. 24.02 ± 
5.52) (Fig. 16). The intravital microscopy revealed rolling and adherent WBC in 
GPIIb wt as indicated by arrows. Rolling and adherent WBCs were also detected in 
GPIIb deficient mice in comparable numbers (Fig. 17). 
Chronic platelet and leukocyte adhesion was detected already in lean 8 to 10 week 
old mice. Moderate leukocyte recruitment occurred in both, GPIIb wild type and 
Knockout mice. Visualization of platelet and leukocyte dynamics was restricted when 
using epifluorescent microscopy because of insufficient optical penetration depth in 
more obese adipose tissue. Also, visualization time was restricted due to insertion of 
tissue damage upon prolonged imaging processes. Although leukocyte adhesion 
events occur already in early stages of fat pad metabolism the analysis using this 
imaging technique was not satisfactory to address consecutively arising questions.  
Thus multiple experimental settings like multi-photon microscopy in WAT were tested 
allowing for prolonged visualization of leukocyte dynamics but in our hands it was 
impossible to reach satisfactory fat tissue stabilization without induction of 
mechanical injury to the visualized adipose tissue.   
We hence used the following set of experiments to address how platelet and WBC 
recruitment reacted in a more advanced stage of obesity. 
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Figure 16: Number of rolling and adherent leukocytes 
WBC adhesion in visceral WAT vasculature was evaluated in GPIIb deficient mice versus wild type 
control. The number of rolling WBC was not reduced in Knockout animals (p.value 0.56) compared to 
wild type mice. WBC adhesion is decreased in GPIIb deficient mice compared to controls (p.value 
0.18). 
 
 
 
 
 
 
 
 
 
Figure 17: Alexa Fluor ® 488 labeled leukocytes in GPIIb wild type and Knockout mice 
Representative freeze images of in vivo microscopy of visceral fat pad vasculature shows firm 
frequent leukocyte adhesion in GPIIb +/+ animals (white arrows) and GPIIb -/- mice. Adherent WBC 
were reduced in GPIIb deficient animals compared to controls. No differences were detected in rolling 
leukocytes between GPIIb deficient and wild type animals. 
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In a next step immunohistological quantification and FACS analysis were used to 
analyze whether chronic inhibition of platelet adhesion culminated in decreased 
leukocyte recruitment to WAT in more advanced stages of WAT expansion. 
Subcutaneous and visceral WAT were harvested of body weight matched 16-17-
week old sex-matched αIIb-deficient and wild type mice and prepared for 
immunohistological and FACS analysis. For the immunohistological analysis of 
leukocyte recruitment WAT was paraffin-embedded, sectioned and stained using a 
monoclonal rat anti-CD45 antibody. The CD45 positive cells were quantified and 
related to the analyzed area (Fig. 18).  
 
Figure 18: CD45+ cell count in WAT of wild type and GPIIb deficient mice 
Left side: Number of CD45+ cells in WAT was evaluated in GPIIb deficient mice versus wild type 
control. The number of CD45+ cells was reduced in Knockout animals (p-value 0.046) compared to 
wild type mice.  
Right side: Representative freeze images of immunohistochemical microscopy of WAT shows 
reduced number of CD45+ cells in GPIIb deficient animals compared to wild type mice (Scale = 20 
µm).  
 
Number of CD45+ cells was reduced in GPIIb deficient mice (p-value 0.046, n = 6, 
2.34 ± 1.59 vs. 1.22 ± 0.62) compared to wild type mice.  
Immunohistological analysis revealed that leukocyte recruitment to WAT was 
impaired in αIIb-deficient mice compared to wild type controls.  
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2. Effect of High Fat Diet on platelet and leukocyte adhesion 
 
The next question was whether platelet adhesion was relevant to assist leukocyte 
adhesion even upon provocation of high-grade inflammatory response in WAT. 
Talukdar et al. showed an aggravation of WAT inflammatory reaction and leukocyte 
recruitment upon high fat or high caloric diet.  
The experiment was set up with 7-week-old αIIb-deficient mice or controls that were 
subjected to high fat diet or control chow. After a control diet for 1 week the animals 
were held on a high fat diet or continuous control diet for 2 weeks respectively. 
Fluorescently labeled platelets and Alexa Fluor ® 488 labeled CD45 antibody were 
administered. At the age of 10 weeks in vivo microscopy of visceral fat depots was 
performed and platelet as well WBC dynamics were evaluated.  
 
Figure 19: Number of rolling and adherent leukocytes normal chow vs. HFD 
WBC adhesion in visceral WAT vasculature was evaluated in wild type mice receiving normal chow 
versus wild type animals that received HFD for 2 weeks respectively. The number of rolling as wells 
as the number of adherent WBC was increased in HFD group compared to animals that received a 
normal diet (p-value 0.005 and 0.09).  
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The number of rolling WBC increased in the HFD group (p-value 0.005, n = 5-6, 
151.70 ± 19.62 vs. 254.08 ± 18.43). There was a tendency to an increase in the 
number of adherent WBC in mice on a HFD (p-value 0.09, n = 5-6, 56.98 ± 14.19 vs. 
105.83 ± 22.58) compared to animals that received normal chow (Fig 19). 
 
Figure 20: Number of rolling and adherent leukocytes normal chow vs. HFD 
WBC adhesion in visceral WAT vasculature was evaluated in Knockout mice receiving normal chow 
versus Knockout animals that received HFD for 2 weeks respectively. The number of rolling 
leukocytes increased slightly in the Knockout animals that were fed a HFD compared to Knockout 
animals that received normal chow (p-value 0.18). No differences were detected in the number of 
adherent WBC in Knockout animals that received a HFD compared to Knockout animals that were fed 
normal chow (p-value 0.34).  
 
 
The number of rolling WBC increased slightly in the HFD group (p-value 0.18, n = 6, 
133.47 ± 23.18 vs. 199.48 ± 40.84) compared to the normal diet group. There was 
nearly no difference in the number of adherent WBC in knockout mice on a HFD (p-
value 0.34, n = 6, 24.03 ± 5.52 vs. 31.85 ± 5.26) compared to Knockout animals that 
received normal chow (Fig. 20, Fig. 21). 
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Figure 21: Alexa Fluor ® 488 labeled leukocytes in GPIIb wild type and Knockout mice after 
high fat diet for 2 weeks 
Representative freeze images of in vivo microscopy of visceral fat pad vasculature shows firm 
frequent leukocyte adhesion in GPIIb +/+ animals after HFD for 2 weeks (white arrows) and GPIIb -/- 
mice after HFD for 2 weeks. WBC adhered firmly to the endothelium in wild type animals after HFD as 
well as Knockout animals after HFD for 2 weeks respectively. 
 
 
 
There was no effect of the HFD on the number of transient adherent platelets (p-
value 0.88, n = 5-6, 57.62 ± 11.63 vs. 60.24 ± 11.33) and the number of adherent 
platelets respectively (p-value 0.29, n = 5-6, 28.19 ± 7.59 vs. 17.62 ± 4.90) (Fig. 22, 
Fig. 23). 
There were similar results in the GPIIb deficient mice concerning the platelets. No 
effect of the HFD on the number of transient adherent platelets was detected (p-
value 0.204, n = 6, 16.88 ± 7.01 vs. 5.06 ± 4.21) and there was no effect on the 
number of adherent platelets respectively (p-value 0.43, n = 6, 3.047 ± 1.97 vs. 0 ± 
0) (Fig. 24). 
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Figure 22: Number of transient adherent and firm adherent platelets normal chow vs. HFD 
Platelet adhesion in visceral WAT vasculature was evaluated in wild type mice receiving normal chow 
versus wild type animals that received HFD for 2 weeks respectively. No differences were detected in 
the number of transient adherent platelets and firm adherent platelets between the wild type animals 
that received normal chow for 2 weeks and the animals that received HFD for 2 weeks (p-value 0.88 
and 0.29).  
 
 
Figure 23: Rhodamine B labeled platelets in GPIIb wild type and Knockout mice after high fat 
diet for 2 weeks 
Representative freeze images of in vivo microscopy of visceral fat pad vasculature shows firm 
frequent platelet adhesion in GPIIb +/+ animals (white arrows) that received HFD for 2 weeks that is 
virtually abolished in GPIIb -/- mice after high fat diet for 2 weeks. 
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Figure 24: Number of transient adherent and firm adherent platelets normal chow vs. HFD 
Platelet adhesion in visceral WAT vasculature was evaluated in Knockout mice receiving normal chow 
versus Knockout animals that received HFD for 2 weeks respectively. No differences were detected in 
the number of transient adherent platelets and firm adherent platelets between the wild type animals 
that received normal chow for 2 weeks and the animals that received HFD for 2 weeks (p-value 0.204 
and 0.43).  
 
 
 
Comparing the number of rolling WBCs between the wild type and the Knockout 
animals both fed a HFD for 2 weeks showed no differences (p-value 0.26, n = 5, 
254.08 ± 18.43 vs. 199.48 ± 40.84). Importantly, WBC adhesion was significantly 
impaired in αIIb-deficient mice compared to wild type siblings after consuming high fat 
diet for 2 weeks respectively (p-value 0.008, n = 5, 100.65 ± 25.42 vs. 31.85 ± 5.26) 
(Fig. 25).  
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Figure 25: Number of rolling and adherent leukocytes wild type vs. KO fed a HFD 
WBC adhesion in visceral WAT vasculature was evaluated in wild type mice receiving high fat diet for 
2 weeks versus Knockout animals that received high fat diet for 2 weeks. No differences were 
detected in the number of rolling leukocytes in wild type animals that received HFD compared to 
Knockout animals that received HFD for 2 weeks respectively (p-value 0.26). The number of adherent 
WBC was significantly reduced in Knockout animals that were fed a HFD for 2 weeks compared to 
wild type animals fed a HFD for 2 weeks (p-value 0.008). 
 
 
 
 
Comparing the number of transient adherent platelets between the HFD groups, 
similar results to the normal diet groups were confirmed. There was a decrease in 
the number of transient adherent platelets in GPIIb deficient mice fed a HFD for 2 
weeks (p-value 0.002, n = 5, 60.244 ± 11.33 vs. 5.06 ± 4.21) compared to wild type 
mice that received a HFD for 2 weeks. There was also a decrease detected in the 
number of adherent platelets in the GPIIb deficient mice fed a HFD for 2 weeks (p-
value 0.03, n = 5, 17.61 ± 4.90 vs. 0 ± 0) compared to wild type animals that 
received a HFD for 2 weeks (Fig. 26).  
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Figure 26: Number of transient adherent and adherent platelets wild type vs. KO fed a HFD 
Platelet adhesion in visceral WAT vasculature was evaluated in wild type mice receiving high fat diet 
for 2 weeks versus Knockout animals that received high fat diet for 2 weeks. There was a significant 
decrease in the number of transient adherent and firm adherent platelets in Knockout animals that 
received a HFD for 2 weeks compared to wild type animals that received HFD for 2 weeks (p-value 
0.002 and 0.03). 
 
 
A significant increase in platelet and leukocyte recruitment was found in the setting 
of high fat diet versus control chow. Importantly, WBC adhesion was impaired in αIIb-
deficient mice compared to wild type siblings after consuming high fat diet.  
Together, platelet-assisted leukocyte adhesion to microvasculature of adipose tissue 
seems to play a pivotal role in lean mice and high fat diet fed animals.   
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3. Fat pad and body weight measurement  
 
As a consecutive step experiments were designed to analyze the effect of blocked 
platelet adhesion and consecutive impairment in leukocyte recruitment to adipose 
tissue phenotype. Therefore, body weight and carcass weight of sex-matched 16-17 
week old αIIb-deficient mice and their wild type controls as well as weight of the 
subcutaneous, visceral, retroperitoneal and brown fat depots were measured. Serum 
leptin concentrations and adipocyte size were measured.  
The GPIIb deficient mice showed a crucial increase in the subcutaneous, visceral as 
well as the retroperitoneal fat pad compared to the wild type animals. The brown fat 
pad showed no increase as typically not relevantly expanding in the setting of 
obesity. No difference in carcass weight was detected, which excluded growth of the 
musculo-skeletal system as the source of weight gain. This initial work was also 
performed by PhD-student T. Konrad and served as the reference point for my 
following experiments.   
The experiments were done using 10-16 week old, sex-matched GPIIb deficient 
mice and their wild type counterparts. Again, body weight and the white fat pads as 
well as the carcass weight were evaluated. The macroscopic view revealed 
significant differences in the white fat pad development already (Data determined by 
Echtler et al.). The fat pad of the αIIb-deficient mice was considerably larger than of 
the wild type counterparts (Fig. 27). 
 
Figure 27: Comparison Fat pad appearance between GPIIb wild type and Knockout 
The fat pad collected from a GPIIb wild type mouse (left side) was substantial smaller than the one 
taken from a GPIIb deficient mouse (right side) (Scale = 2 mm) 
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3.1. GPIIb deficient and wild type mice  
 
T. Konrad analyzed whether there are differences in the body weight between GPIIb 
deficient mice and their wild type counterparts and was able to show a weight 
increase in GPIIb deficient animals compared to wild type controls.  
He also measured serum leptin levels between GPIIb deficient and wild type 
animals, showing higher serum leptin levels in αIIb-deficient mice compared to wild 
type animals. 
T. Konrad also analyzed the adipocyte size and showed an increase of adipocyte 
size in GPIIb deficient mice compare to wild type mice. Further metabolic screenings 
revealed no differences in food consumption, energy expenditure or physical activity 
in αIIb-deficient mice versus controls. This excluded that the observed differences in 
the WAT depend on alterations of energy intake/uptake, kinesic behavior or 
metabolism. 
A set of experiments were performed to assess in more detail whether the observed 
effects was really a platelet-mediated process. As described αIIb-Expression is 
restricted to the hematopoietic lineage (73). Early bone-marrow resident 
hematopoietic progenitors and megakaryocytes, as well as platelets and some mast 
cells are known to express αIIb. Using whole mount embryo staining techniques 
Emambokus et al. could not detect any further tissue αIIb-expression.  
 
 
 
 
 
 
 
 
 
 
Results  79 
3.2. GPIIb deficient and wild type bone marrow chimera mice 
 
Bone marrow chimera of αIIb-deficient and wild type mice were created to restrict the 
GPIIb ablation to the hematopoietic system for a further verification that platelets are 
crucial for the regulation of WAT inflammation. Therefore 8-week-old female 
C57Bl/6J mice were sublethally irradiated and received either αIIb-deficient or wild 
type bone marrow cells of female donor mice. 16 weeks after the transplantation the 
body weight and fat pad weight was measured.  
Figure 28: Total WAT quantification between GPIIb deficient and wild type chimera mice 
Total WAT weight was evaluated in C57Bl/6J mice after receiving wild type or αIIb-deficient bone 
marrow cells. There was a significant increase in the total WAT weight evaluated in C57Bl/6J mice 
after that αIIb-deficient bone marrow cells compared to evaluated in C57Bl/6J mice that received wild 
type bone marrow cells (p-value 0.04). 
 
 
A measurement of the total WAT amount revealed an increase in the GPIIb deficient 
chimera mouse group (p-value 0.04, n = 6, 0.477 ± 0.034 vs. 0.567 ± 0.0153) 
compared to the wild type chimera group (Fig. 28).  
A closer look at the single fat pads of bone marrow chimera mice revealed an 
increase in the visceral fat (p-value 0.12, n = 6, 0.26 ± 0.03 vs. 0.31 ± 0.01) as well 
as in the abdominal fat pad (p-value 0.005, n = 6, 0.08 ± 0.01 vs. 0.12 ± 0.01).  
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The subcutaneous fat pad did not increase in GPIIb deficient mice (p-value 0.66, n = 
6, 0.14 ± 0.01 vs. 0.135 ± 0.01) as being directly exposed to the irradiation, which 
badly influences the fat pad formation (Fig. 29).  
The brown fat in the GPIIb deficient mice showed no weight gain (p-value 0.66, n = 
6, 0.10 ± 0.01 vs. 0.11 ± 0.01), as brown adipose tissue is mainly responsible for 
energy production and not energy storage.  
Figure 29: WAT depots of GPIIb deficient and wild type chimera mice in detail 
WAT and BAT depot weight was evaluated in C57Bl/6J mice after receiving wild type or αIIb-deficient 
bone marrow cells. There was an increase in the visceral and abdominal WAT weight in C57Bl/6J 
mice after receiving αIIb-deficient bone marrow cells compared C57Bl/6J mice that received wild type 
bone marrow cells (p-value 0.12 and 0.005). No differences were detected in the subcutaneous WAT 
and the brown fat pad weight in C57Bl/6J mice after receiving αIIb-deficient bone marrow cells 
compared to C57Bl/6J mice that received wild type bone marrow cells (p-value 0.66 and 0.65) 
 
The generation and evaluation of GPIIb bone marrow chimera mice substantiated 
the notion, that platelets, which abundantly surface-express αIIbβ3-integrin integrin, 
mediate the observed regulatory processes of WAT expansion.  
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4. Analysis of fat pad vascularization 
 
Our group also tested whether an alteration of WAT expansion could also be 
observed in other transgenic mice with impaired platelet function. For this reason, 
the fat depots of NFE2-deficient mice on a mixed C57BL/6 x SV129 background 
were analyzed. The NFE2 mice show a disturbed megakaryopoiesis and 
homozygous animals reveal virtually no circulating blood platelets with a smaller 
number of remaining functional platelets (142). As a result, the animals show 
frequent bleeding events and anemia.  
Since novel vessel formation or growth of pre-existing vessels might play a role in 
adipose tissue expansion, we analyzed whether alterations in fat pad circulation 
occurred in αIIb-deficient mice versus control. 
For this reason, vessels were stained using a CD144-antibody; the subcutaneous fat 
depots were collected and subjected to multiphoton microscopy. The vessel 
structure was visualized 3-dimensionally and the vessel density was determined 
(Fig. 30).  
Evaluation of the vessel structure in the subcutaneous fat pads of GPIIb deficient 
mice and their wild type counterparts revealed no difference between the two groups 
(p-value = 0.892, t-test, n = 4, wt mean = 1.93 ± 0.21, KO mean = 1.87 ± 0.67) (Fig. 
31), implicating that differences of cell interactions within the various phenotypes are 
mainly due to the impaired GPIIb Integrin functions and not due to vascular 
variations and the related changes in cell counts. 
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Figure 30: Three-dimensional visualization of CD144 stained subcutaneous fat pad vasculature 
Representative freeze images of two photon microscopy of subcutaneous fat pad vasculature.          
No differences between GPIIb deficient mice and their wild type counterparts were detected          
(scale = 25 µm).  
 
 
From the first part of the thesis it can be concluded that chronic platelet adhesion 
occurs in adipose tissue vasculature even at early stages of adipogenesis. This 
platelet adhesion enables leukocyte recruitment to WAT depots in the process of fat 
depot expansion. 
Local adhesion of platelets is impaired in αIIb-deficient mice; this was paralleled by a 
decrease in leukocyte adhesion and an increase in WAT enlargement. Latter was 
reflected by the expansion of WAT depots (subcutaneous, visceral and 
retroperitoneal) as well as body weight. The carcass weight remained unaltered in 
knockout animals showing that the increase in weight was not due growth of the 
musculo-skeletal system. 
As a following step of the project the underlying factors of the observed effects were 
further analyzed. Chemokine mRNA-expression analysis in subcutaneous fat depots 
of αIIb-deficient and control animals were evaluated. No difference in the expression 
of Chemokine ligand 1 (CXCL1), which is one of the first factors to be released in the 
neutrophil signal transduction cascade on the site of inflammation, was found (p-
value 0.13, n = 4, 0.97 vs. 0.73) between wild type and Knockout animals. 
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Figure 31: Quantification of vessel per fat pad volume in subcutaneous fat pad 
Vessel volume per fat pad volume in subcutaneous WAT was evaluated in wild type mice versus 
GPIIb Knockout animals using two-photon microscopy. No differences were detected in the 
percentage of vessel per fat pad between wild type and Knockout animals (p-value 0.89).  
 
There were also no differences in the expression of Chemokine ligand 5 (CXCL5) (p-
value 0.58, n = 4, 0.46 vs. 1.62) and Chemokine ligand 2 (CXCL2) (p-value 0.87, n = 
4, 1.04 vs. 1.00), that also play a crucial role in the inflammatory leukocyte signal 
transduction cascade, between wild type and GPIIb deficient mice. The levels of the 
inflammatory marker Interleukin 6 (IL-6) was also comparable between the two 
groups (p-value 0.26, n = 4, 1.52 vs. 0.53). 
Despite the detected increase in WAT expansion in αIIb-deficient mice, Tumor 
necrosis factor α (TNF-α) mRNA-expression was significantly reduced in 
subcutaneous WAT of αIIb-deficient animals compared to their wild type counterparts 
(p-value 0.04, n = 4, 0.64 vs. 0.42). There were reports of TNF- α deficient animals 
that showed enlarged WAT depots after receiving high fat diet (210).  
Therefore, it was further tested whether platelets and leukocyte recruitment could 
affect TNFα expression of adipocytes and adipocyte biology.  
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5. In vitro culture of adipocytes  
 
The different behavior of platelets and leukocytes after adherence to the 
dysfunctional endothelium of the adipose tissue vasculature consists of their 
influence on adipocyte biology. While leukocytes could directly interact with 
adipocytes after transmigration into the adipose tissue and thus change the TNF-α 
expression levels of these cells, platelets could influence adipocytes only via 
paracrine effects. Platelets probably might release pro-inflammatory substances 
while interacting with the dysfunctional endothelium of adipose tissue.  
When presumed that platelets after becoming adherent to the dysfunctional 
endothelium of the adipose tissue vasculature would release multiple, partly pro-
inflammatory substances could in this way influence adipocytes only in a paracrine 
manner. Leukocytes, in contrast could - apart from paracrine effects mediated by 
adherent platelets - additionally directly interact with adipocytes after transmigration 
into the adipose tissue and by this way change TNF-α expression in adipocytes.  
For this reason murine 3T3-L1 preadipocytes were purchased from ZenBio, Inc. 
(USA). These cells derived from mouse 3T3 cells and are well established for the 
research on adipose tissue and show a fibroblast like morphology with the ability to 
differentiate into an adipose like phenotype over a period of 14 days (Fig. 32).  
Preadipocytes were delivered and seeded at passage number 8 and splitted until 
passage number 10, the cells grew in density and developed a fibroblast-like 
structure (Fig. 32 A). After a strict differentiation phase of three days the 
preadipocytes started to enrich with lipids (Fig. 32 B). This process took about 14 
additional days with further enrichment of triglyceride lipids, forming larger lipid 
droplets (Fig. 32 C) and resulted in mature adipocytes with one large lipid vacuole 
(Fig. 32 D).  
Experiments were done during the differentiation phase as well as with mature 
adipocytes after the developmental process took place. 
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Figure 32: Preadipocyte to adipocyte development 
The cells were stained using Sudan III for a better visualization. The development/maturation process 
took about four weeks from the preadipocyte to the mature adipocyte (Scale = 20µm).  
 
 
5.1. TNF-α ELISA after adipocyte treatment 
 
Murine mature adipocytes were co-incubated with different substances after the 
developmental processes were finished to evaluate whether these pro-inflammatory 
substances released by platelets and leukocytes could influence the TNF-α 
expression in adipocytes. The adipocytes were co-incubated with ADP-activated 
platelet supernatant, activated platelets, isolated murine polymorphonuclear 
leukocytes (PMA activated or unstimulated) or controls for 3 or 6 hours, washed and 
adipocyte TNF-α protein expression was assessed 18 hours thereafter. 
While no TNF-α expression was detectable in controls (ADP, PMA, Tyrodes), a 
robust TNF-α expression was found in adipocytes treated with activated PMNs 
(mean = 133.24 ± 8.21, n = 3) and unstimulated PMNs (mean = 139.97 ± 9.62, n = 
3). Treatment with platelet supernatant had no effect on TNF-α production in murine 
adipocytes (Fig. 33). Also co-incubation with activated platelets had no effect on the 
TNF-α expression. However, the combination of activated platelets with 
polymorphonuclear leukocytes, as well as the combination of inactivated platelets 
with PMNs caused TNF-α expression. 
A B C D 
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Figure 33: Cell culture supernates TNF-α levels after stimulation 
Treatment of mature adipocytes for 3h after development phase revealed TNF-α expression in the 
groups treated with PMNa, PMN, PLTa+PMN and PLT+PMN. 
 
 
5.2. Adipocyte proliferation evaluation 
 
After getting a first impression on the TNF-α expression levels of mature adipocytes, 
cells were treated with TNF-α and other substances already during their 
differentiation phase as well as during the maturation phase to evaluate their 
proliferation behavior. 
Cells were treated a total of three times each 24 hours. The first treatment was 
during day two and day three of the differentiation phase, the second treatment at 
day 8 of the maturation phase and the third treatment on day 14 of maturation 
phase. 
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Figure 34: Area covered with adipocytes 
A significant reduction of area covered with adipocytes was detected in the groups treated with PMNa, 
PMN, PLTa SN and TNF-α compared to cells treated with tyrodes buffer. No differences were 
detected in the groups treated with PLTa+PMN, PLTa, PBS+PMS and Tyrpdes+ADP compared to 
cells treated with tyrodes buffer (* = significance vs. Tyrodes group). 
 
 
The proliferation was measured as the percentage of covered area per well using a 
phase contrast microscope. For a better differentiation the cells were first stained 
using Sudan III, however using ImageJ for evaluation made staining unnecessary as 
the experiments were repeated.  
There was a decrease in the adipocyte covered area in the PMNa group compared 
to the control group treated with Tyrodes buffer (p-value 0.001, n = 2 biological 
replicates, 6 technical replicates, 41.03 ± 2.58 vs. 57.83 ± 2.25), in the group treated 
with PMN (p-value 0.002, n = 2 biological replicates, 6 technical replicates, 43.29 ± 
2.52), in the group treated with PLTa SN (p-value 0.03, n = 2 biological replicates, 6 
technical replicates, 49.27 ± 2.63), as well as in the group treated with TNF-α 1ng (p-
value 0.001, n = 2 biological replicates, 6 technical replicates, 44.49 ± 1.67) and the 
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group treated with TNF-α 10ng (p-value 0.001, n = 2 biological replicates, 6 technical 
replicates, 38.43 ± 2.21). There was a decreasing tendency in the group treated with 
PLTa (p-value 0.18, n = 2 biological replicates, 6 technical replicates, 53.19 ± 1.05). 
The groups treated with PLTa + PMN (p-value 0.73, n = 2 biological replicates, 6 
technical replicates, 56.46 ± 3.1), PBS + PMA (p-value 0.28, n = 2 biological 
replicates, 6 technical replicates, 60.88 ± 1.44) and Tyrodes + ADP (p-value 0.65, n 
= 2 biological replicates, 6 technical replicates, 59.09 ± 1.38) did not differ from the 
Tyrodes treated control group (Fig. 34). 
 
Figure 35: Microscopic images of adipocyte covered wells 
Representative images of microscopy of adipocytes in vitro after stimulation with different substances 
 (scale = 300 µm). 
 
 
Different treatments of adipocytes resulted in a proliferation change. This was 
detectable already by eye as seen in Figure 35. The groups treated with TNF-α 
showed obvious changes in the area covered with adipocytes. These significant 
changes occurred also in the groups with leukocytes (PMNa and PMN) as well as 
the platelet supernatant group. 
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6. TNF-α blockade via Infliximab  
 
For further evidence, that reduced TNF-α production in a lean mouse model 
culminated in an expansion of white adipose tissue, TNF-α was blocked in vivo and 
the fat deposition weight was evaluated as described before. 
Therefore, Infliximab (Remicade®), a chimeric monoclonal antibody directed against 
TNF-α ligand and membrane-bound TNF-α or a vehicle (NaCl, 0.9%) was given 
intraperitoneally once a week over 6 weeks to adult C57BL/6 mice. The mice were 
weighed directly before the treatment. After the treatment period mice as well as 
their fat pads were weighed again. TNF-α serum levels were assessed using ELISA 
to evaluate a successful TNF-α blockade (Fig. 36). 
 
Figure 36: Measurement of serum TNF-α levels using ELISA 
Serum TNF-α levels were evaluated in wild type mice receiving a vehicle for 6 weeks and mice 
receiving Infliximab for 6 weeks. Serum TNF-α levels were significantly decreased in mice treated with 
Infliximab compared to vehicle treated mice (p-value 0.02).  
 
After 6 weeks of treatment clearly reduced TNF-α serum levels in animals treated 
with Infliximab (starting age 60-70 days) were found compared to vehicle control (p-
value = 0.02, n = 5-6, 3.19 ± 0.26 vs. 2.17 ± 0.26).  
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Infliximab treatment provoked an increased body weight gain compared to vehicle 
controls (p-value = 0,01, n = 6, 1.63 ± 0.28 vs. 2.88 ± 0.32) (Fig. 37).  
 
Figure 37: Total weight gain after Measurement of serum TNF-α levels using ELISA 
Weight gain was evaluated in wild type mice receiving a vehicle for 6 weeks and mice receiving 
Infliximab for 6 weeks. Weight gain was significantly increased in mice treated with Infliximab 
compared to vehicle treated mice (p-value 0.01).  
 
Already after 6 weeks of treatment, the animals that received Infliximab showed a 
clear and prominent increase in weight gain. This highlights the crucial role of TNF-α 
in the development of WAT and the inflammatory characteristics during 
adipogenesis.  
To get an even more detailed impression of the weight gain in mice treated with 
Infliximab, the mice were anesthetized after the 6-week treatment and the fat pads 
were measured as described before. 
All analyzed WAT depositions showed clear enlargement in Infliximab® treated 
animals, compared to vehicle treated groups, although results did not reach 
significance after 6 weeks of treatment (Fig. 38) (WAT total weight p-value 0.37, n = 
9, Infliximab mean = 0.74 ± 0.09, vehicle mean = 0.63 ± 0.06, subcutan fat pad p-
value 0.33, n = 9, Infliximab mean = 0.24 ± 0.02, vehicle mean = 0.22 ± 0.02, 
visceral fat pad p-value 0.48, n = 9, Infliximab mean = 0.38 ± 0.07, vehicle mean = 
0.33 ± 0.04, abdominal fat pad p-value = 0.17, n = 9, Infliximab mean = 0.10 ± 0.01, 
vehicle mean = 0.08 ± 0.01).  
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Figure 38: White fat pad measurement after Infliximab and vehicle treatment 
WAT total weight and WAT weight was evaluated in wild type mice receiving a vehicle for 6 weeks 
and mice receiving Infliximab for 6 weeks. No differences were detected in the visceral fat pad 
between animals treated with Infliximab and animals treated with the vehicle (p-value 0.48). There 
was a decrease in subcutaneous and abdominal fat pad weight in animals treated with Infliximab 
compared to vehicle treated animals (p-value 0.33 and 0.17). 
 
Interestingly, there was a clear increase in subcutaneous as well as abdominal fat 
pads of animals treated with Infliximab. Although the treatment lasted only 6 weeks it 
leads to this results, highlighting the important role of TNF-α in the development of 
WAT again.  
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To summarize, chronic platelet and leukocyte adhesion to vasculature of white 
adipose tissue was detected already at early stages of WAT expansion. Using 
immunohistochemical analysis and in vivo microscopy impairment of platelet 
adhesion by a lack of αIIb-β3 integrin was detected, that consecutively culminates in 
diminished leukocyte recruitment to WAT depots in lean and HFD-fed mice, resulting 
in an increased WAT expansion.  
In vitro analysis of adipocytes revealed that leukocytes not only delivered TNF-α to 
WAT but also were able to provoke upregulation of TNF-α expression in adipocytes. 
Co-incubation of adipocytes with leukocytes or TNF-α inhibited adipocyte growth.  In 
line, subcutaneous fat depots of αIIb-deficient animals revealed reduction of recruited 
leukocyte numbers in the WAT, reduced TNF-α expression and expanded white 
adipose depots. Consequently, blocking TNF-α in vivo with Infliximab provoked 
weight gain in a lean mouse model.  
In this way, a novel axis in adipose tissue homeostasis was revealed with platelet-
assisted leukocyte recruitment that provoked upregulation of TNF-α expression and 
in this way -at least in part- control fat pad expansion.  
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VI. DISCUSSION 
1. Experimental procedure 
1.1. Choice of mouse strain 
 
The mouse was chosen as a research animal because of its easy to manipulate 
genetics on one side, as well as its short reproduction time on the other side 
including a large number of descendants. That is why there are many genetical 
knockout strains available for addressing various immunological questions.  
Working in an animal model is necessary to address the role of platelets and 
neutrophils in the pathogenesis of obesity not only in an in vitro model, but also with 
in vivo experiments. The animal model allows for analysis of platelet-leukocyte 
interactions as well as observation of animal behavior and physiology under certain 
conditions like a different feeding regime but it makes it also possible to compare the 
pathophysiology of different genotypes.  
The GPIIb Knockout strain was chosen, because it facilitates the analysis of 
potentially platelet driven and GPIIb mediated effects and the platelet dependent 
interactions with leukocytes in the pathogenesis of obesity. Due to the crucial role of 
the GPIIb (αIIbβ3) integrin in the platelet adhesion and fibrinogen-mediated activation 
process, a knockout of this integrin enables a highly appropriate animal model for 
studying platelet dependent effects (38, 219). Besides fibrinogen-mediated activation 
and aggregation processes (102, 108) the GPIIb/IIIa complex is highly important for 
platelet adhesion to the intact endothelium (203, 244) as well as signal transduction 
after binding (168, 197). The GPIIb receptor also mediates the adhesion of platelets 
on the dysfunctional endothelium (240, 244) and triggers secretion of various pro-
inflammatory cytokines via outside-in-signaling (90, 220-222, 224). 
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2. Discussion of results 
2.1. Platelet and leukocyte adhesion in visceral fat 
 
In vivo microscopy of visceral adipose tissue revealed, that firm platelet adhesion to 
the vasculature of WAT already occurred during the initiation of obesity in the 
subcutaneous fat pad of GPIIb wild type mice. The data suggest, that the observed 
chronic platelet adhesion consecutively facilitates recruitment and infiltration of 
leukocytes into adipose tissue. This again culminates in a restriction of adipose 
tissue expansion.  
With attenuation of platelet adhesion in GPIIb deficient mice as well as lack of 
platelets in NFE2 Knockout mice enhanced WAT expansion compared to the wild 
type counterparts can be observed. 
An activation of endothelial cells is also described as endothelial dysfunction, 
representing an early pathophysiological feature in many acute and chronic 
inflammatory processes. Platelets also act as a major player in the initiation of the 
atherogenic process by adhering to the vascular endothelium before the 
development of manifest atherosclerotic lesions (158). The integrin GPIIb/IIIa on 
platelets mediates platelet aggregation and triggers platelet adhesion to the exposed 
extracellular matrices as well as dysfunctional endothelial cells contributing for 
instance to the pathogenesis of cerebral Ischemia/Reperfusion injury (161). Platelets 
also act as a major player in the initiation of the atherogenic process by adhering to 
the vascular endothelium before the development of manifest atherosclerotic lesions 
(158) and the progression of deep vein thrombosis (DVT). They have been shown to 
promote leukocyte recruitment (158) and stimulation of neutrophil dependent 
coagulation, here revealing a functional crosstalk between platelets and neutrophils 
(253).  
Also in adipose tissue endothelial activation has been shown to be a common 
feature of chronic inflammatory processes (262, 268). 
Upon activation the endothelial cells shift towards an increase in pro-adhesive 
properties by upregulation of P-Selectin (149) and other endothelial cell adhesion 
molecules like E-selectin, ICAM-1 and VCAM-1 (55). This reveals a reduction in/ 
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downregulation of endothelial nitric oxide synthetase (61) as well as upregulation of 
surface deposition of adhesion molecules like von Willebrand factor (141) allowing 
for even more adhesion of circulating blood cells.  
Platelet adhesion represents a typical response to endothelial activation with strong 
effects on subsequent inflammatory processes. For this reason, it was analyzed to 
what extent platelets interact with activated endothelium of adipose tissue 
vasculature. To do so, in vivo microscopy was performed in wild type versus αIIbβ3-
deficient transgenic mice. 
Endothelial activation occurs in many forms of pathogenensis with chronic 
inflammation like Rheumatoid Arthritis (10), Systemic Lupus Erythematosus (266) or 
Psoriasis (29). Also in obesity endothelial activation seems to occur  (183). 
Endothelial activation leads to platelet adhesion in atherosclerosis/I/R-injury/ DVT 
(158-161, 253). In these examples of vascular inflammation platelet adhesions 
supports WBC recruitment and in this way further aggrevates inflammatory 
processes (253). In vivo microscopy here shows platelet adhesion in visceral 
fatpads. Neutrophil accumulation seems to enhance, however significance is not 
reached in lean anmals, it has to be mentioned, that subtle effects might be lost due 
to the small time window within the intravital microscopic analysis. However, an 
enhanced accumulation of leukocytes was found in adipose tissue seven weeks later 
by performing flow cytometric and immunohistological analysis compared to the wild 
type animals. 
 
The depots of adipose tissue occur in multiple visceral and subcutaneous fat pads of 
the body. There is strong clinical evidence indicating adipose distribution is important 
since central obesity is typically associated with metabolic and vascular 
complications (82). Especially the visceral fat pad is not only a simple fat-storage 
side but rather has to be understood as an endocrine organ with high inflammatory 
potential (53).  
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Figure 39: Model of leukocyte and platelet interation on adipose microvasculature endothelium 
The scheme gives an overview of how the interaction of leukocytes (blue) and platelets (red) on the 
micovasculature endothelium take place. The cell components can be distinguished by color. 
 
 
 
The adhesion of platelets on endothelial rolling leukocytes is the initial step of a 
multistep process. This process leads to an extravasation of white blood cells to sites 
of inflammation. The first part of the thesis suggests that this model is also true for 
the vasculature of adipose tissue (Fig. 39). 
The platelets may also interact with the endothelium in the absence of 
perceptible/visible morphological damage. They probably may stick to an apparently 
intact endothelium that is inflamed and influenced by stimuli from site of adipose 
tissue. A mechanism by which adipose tissue inflammation promotes the vascular 
dysfunction is unclear, however endothelial dysfunction has already been described 
in obese children (15, 247).  
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Recruitment of leukocytes to vascular injury after interaction with activated platelets 
is a rapid response that is initially mediated by release of endothelial components 
like von Willebrand factor and P-Selectin. 
P-Selectin mediates platelet adhesion but also initiates the process of leukocyte 
rolling (250). Activated platelets at the site of vascular damage play a pivotal role in 
leukocyte accumulation, also for example in growing thrombi (253) and may 
therefore also be from high importance in the recruitment and migration of 
leukocytes through the vessel wall. 
After van Willebrand factor mediated activation platelets form complexes with 
leukocytes via PSGL-1 (139). These platelet-leukocyte complexes promote 
activation of leukocytes. Furthermore these complexes also produce chemokines, 
that might facilitate the recruitment of leukocytes into adipose tissue after deposition 
to the vessel wall (255). 
 
2.2. Effect of High Fat Diet on platelet and leukocyte adhesion 
 
Experiments illustrate how an impaired platelet adhesion in αIIbβ3 (GPIIb) or 
complete lack of platelets (NFE2) culminates in significant WAT expansion. This was 
shown in early studies of our group performed in GPIIb and NFE2 deficient mice. It is 
known that chronic inflammatory processes in obesity are enhanced when high fat 
diet is administered. Talukdar et al found a significant increase of neutrophil 
infiltration adipose tissue in mice, that were held on a HFD for two weeks. Putting the 
animals on a high fat diet also provoked high-grade inflammatory response (238). In 
conforming fashion increase in platelet and WBC adhesion was shown in lean 
versus HFD controls.  
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Free Fatty Acids (FFA) must cross the capillary endothelial cells to be available for 
adipocytes. After consuming a high fat diet or even a high fat meal, excessive FFA 
formation might trigger acute inflammatory events in the adipose tissue. These 
inflammatory events are likely to result in exposure of vWF (148, 252) and fast 
displacement of P-Selectin to the endothelial cell-surface (162). An upregulation of 
endothelial cell adhesion molecules was also demonstrated in healthy patients 
following intake of high fat meals (225).  
Actions of the microcirculation caused by high fat diet might more importantly trigger 
a GPIIb dependent firm platelet adhesion after interaction with vWF, resulting in 
platelet interaction with leukocytes and moreover trafficking of leukocytes into 
adipose tissue. 
Most intriguing outcome of the high fat diet experiments was the impaired WBC 
adhesion in αIIbβ3-deficient mice compared to wild type siblings due to a reduced 
GPIIb dependent firm platelet adhesion and furthermore a reduced platelet and 
leukocyte interaction. 
It has to be mentioned that the experimental setup was able to replicate and confirm 
the hypothesis of Talukdar et al., showing an increase in the number of migrating 
neutrophils into the adipose tissue after high fat diet already in Wild type mice.  
It was not only feasible in our experimental setup to show a significant increase in 
the number of rolling leukocytes even after two weeks of HFD, but also an obvious 
trend indicating an increase in the number of adherent leukocytes, performed in wild 
type animals.  
The number of rolling WBC increased slightly in the HFD Knockout group, indicating 
not only a role of P-Selectin binding to Leukocytes via PSGL-1 (129, 170, 185) but 
also a prominent role of platelet interaction with leukocytes that facilitates the 
migration of leukocytes into adipose tissue. Less platelet adhesion to the 
endothelium due to the GPIIb deficiency led to less interaction of platelets with 
leukocytes and therefore less leukocyte migration to adipose tissue. 
Data is consistent to what you have already seen in immunohstochemical analysis 
with reduced WBC accumulation in GPIIb deficent mice compared to the Wildtype 
group. 
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Taken together, the sheer numbers of rolling and adherent WBC were smaller in 
Knockout animals than in their wild type counterparts due to the αIIbβ3-deficient 
genotype along with platelets incapable of adhering to the endothelium via vWF and 
consequently unable to assist leukocytes migrating into the adipose tissue.  
However, HFD raised these numbers in both genotypes by confronting leukocytes 
with a quite more dysfunctional endothelium through to diet-induced release of FFA 
linked with displacement of endothelial vWF and P-Selectin. 
This allowed us detecting the most intriguing outcome of this HFD experiment. 
Although the difference in rolling leukocytes between wild type and Knockout 
animals both fed a HFD might not differ that much from each other by presenting just 
a slight increase in the wild type group, difference between the adherent leukocytes 
is quite remarkable. There is an explicit decrease in the number of adherent 
leukocytes in αIIbβ3-deficient animals compared to wild type mice both fed a HFD.  
This effect can again be attributed to the HFD induced higher count of rolling and 
adhering leukocytes, illustrating the very likely platelet specific role of leukocyte 
assistance in migrating into adipose tissue after platelet interaction with leukocytes. 
The distinctness of this effect would not have been possible to demonstrate in a lean 
animal model to this extent.  
Additionally, comparison of transient adherent and firm adherent platelets in a HFD 
setting remains identically to the previously described lean experimental setting, 
proving that the high caloric diet had no impact on the platelet behavior but obviously 
changed leukocyte dynamics significantly. 
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2.3. Fat pad and body weight measurement 
2.3.1. Transgenic GPIIb deficient and wild type mice 
 
In a next step it was tested whether the observed decrease in WBC adhesion had 
functional effects on adipose tissue phenotype. To do so body weight was measured 
in transgenic GPIIb wild type and Knockout mice. 
Evaluation of body weight and fat pad analysis already revealed significant fat pad 
expansion in GPIIb-deficient mice compared to wild type controls (Konrad et al., 
unpublished data). Dong et al. found that Mice deficient in ICAM-1 became 
spontaneously obese in old age (69), which also supports our findings of a 
connection between impaired cell adhesion to the adipose tissue endothelium and 
increase in body weight. In contrast, Yang et al. found, that P-selectin deficiency 
protects against an increase of body weight after high-fat diet (271), affirming a 
crucial role of GPIIb integrin mediated platelet adhesion resulting in platelet-
leukocyte interaction and leukocyte migration into adipose tissue, as examined in 
this thesis. 
The body weight was again measured in transgenic GPIIb wild type and Knockout 
mice to further evaluate the link between platelet-leukocyte interaction on the 
dysfunctional endothelium in adipose tissue and the potentially related WAT 
expansion 
The visceral fat pad is the most crucial representative for meta-inflammatory 
processes, meaning inflammatory responses like cytokine production (104), 
activation and recruitment of circulating leukocytes (260) and the remodeling of 
adipose tissue (110).  Therefore, it was directly and most likely influenced by 
leukocyte-platelet mediated migration of leukocytes into the adipose tissue. The 
retroperitoneal and the subcutaneous fat pad showed also expansion in the 
experimental setup as well, however not in the extent of the visceral fat.  
The brown fat pad was not affected by weight gain, as is main function presents heat 
production by non-shivering thermogenesis. It does not store energy in form of fat. 
However, in some cases it was hard to distinguish between BAT and WAT as the 
brown fat was somehow covered by a thin layer of white fat pad.  
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The animals showed no differences in carcass weight, this ruled out that weight gain 
occurred only due to enhanced musculoskeletal growth. 
Serum leptin levels revealed a significant increase in αIIbß3 deficient animals. 
Typically correlating with the BMI (56), leptin levels are also reported to correlate 
with a number of endocrine substances such as insulin and thyroid hormones (115). 
The primary function of leptin is to appear as an anti-obesity hormone by 
suppressing the hungry feeling in the hypothalamus (172). Being expressed primarily 
by adipocytes, the correlation of fat pad weight and serum leptin levels detected in 
this work seems completely comprehensible. 
The associated increase of adipocyte size in αIIbß3 deficient animals also supports 
position of literature. Obesity is defined as enlargement of adipose tissue to store 
surplus energy intake. Two possible mechanisms are the increase in cell number 
(Hyperplasia) as well as the increase in cell size (Hypertrophy). While hyperplastic 
growth appears only at early stages of adipose development (21), hypertrophic 
growth is more common, meeting the need for additional fat storage capacity (114).  
Being crucially influenced by the lack of platelet-leukocyte mediated migration of 
leukocytes into the adipose tissue, αIIbß3 deficient animals develop larger adipocytes 
due to hypertrophic growth. Leukocyte migration seems somehow to control and 
mitigate energy intake of adipocytes. Absence of this trigger compels adipocytes to 
cope with their high-energy rate by hypertrophic events.  
To validate in this first part of the project that the observed effects are in fact platelet 
driven effects, mRNA analysis was performed in a large selection of adult tissues to 
assess whether probably so far unidentified αIIbß3-expression occurred in adult 
mouse tissues. As already mentioned, αIIbß3 is also expressed in bone-marrow 
resident hematopoietic progenitors and megakaryocytes (78),  as well as in some 
mast cells (189). 
No expression was detected in most tested organs. Slight mRNA-levels in liver and 
kidney were found probably most due to platelet contamination. However, mRNA 
analysis affirmed the theory that platelet resident αIIbß3 as being solely accountable 
for the platelet-leukocyte mediated adipose tissue development. 
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2.3.2. GPIIb deficient and wild type bone marrow chimera mice 
 
For further test whether it was a platelet specific process that influenced WAT 
expansion in Knockout mice, bone marrow chimera mice were created to distinguish 
the contribution of hematopoietic cells versus non-hemapoietic cells (270). After 
sublethally irradioation, 8-weeks old C57Bl/6J wildtype animals either received αIIbß3 
or wildtype bone marrow cells of sex matched donor mice. Body weight and fat pad 
weight were assessed 16 weeks after transplantation. 
The total WAT amount showed an increase in the GPIIb deficient chimera group 
compared to their wild type counterparts. 
Once more, αIIbß3-deficient bone-marrow chimera revealed a significant increase in 
WAT expansion, implying transplantability of the GPIIb integrin mediated effect. This 
further substantiates the notion, that αIIbβ3-integrin expressing platelets mediate the 
observed regulatory processes in WAT expansion. 
Brown fat pad as well as the carcass weight of Knockout and wild type chimeric mice 
were from equal measure in both genotypes. This again confirmed the previous 
findings in transgenic mice. Besides the fact that the brown fat pad is not influenced 
when it comes to weight gain due to its exclusive non-shivering thermogenesis 
behavior it also demonstrates once more, that the weight gain measured in GPIIb 
deficient animals was due to expansion of WAT and excluded a growth of the 
musculo-skeletal system as weight gain source. 
 
2.4. Analysis of fat pad vascularization 
  
Vascularization of the fat pads was analyzed using multiphoton microscopy to 
identify the potential role of de novo vessel formation or growth of pre-existing 
vessels within the expansion of adipose tissue. 
Work of our group showed GPIbα-mediated platelet-leukocyte interactions to directly 
support innate immune cell recruitment and further promote arteriogenesis in a 
mouse model of hindlimb ischemia (44). 
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Hence, multiphoton microscopic analysis was used to investigate whether 
differences in cellular interactions on the dysfunctional adipose tissue endothelium 
as well as alterations of WAT expansion rates were only due to significant 
differences in novel vessel formation or vessel growth within these genotypes.  
Arteriogenesis, usually linked to an increase in blood pressure, is also related to an 
upregulation of inflammatory cytokines and cell adhesion receptors. After increase of 
shear stress, monocyte chemo-attractant protein-1 (MCP-1) is highly expressed on 
the surface of vessel walls. This accompanies also with increased levels of TNF-α 
and matrix metalloproteinase (MMP). MMP remodel the space around the vessel, 
providing space for expansion (248). Also nitric oxide (NO) is reported to be a major 
factor in vessel diameter enlargement in response to increased blood flow (245).  
However, no difference in vessel density between the groups was found, thus 
eliminating the hypothesis, that the observed effects described in the previous 
chapters were ascribed to changes and differences in vessel formation between the 
genotypes. 
 
2.5. In vitro culture of adipocytes 
2.5.1. TNF-α ELISA after adipocyte treatment 
 
To further investigate underlying determinants of the observed effects, chemokine 
mRNA-expression in subcutaneous fat depots of wild type and GPIIb Knockout 
animals was performed revealing significantly reduced expression of TNF-α (mRNA) 
in αIIbβ3-deficient animals. In line, enlarged WAT depots were reported in TNF-α 
deficient animals after receiving HFD (210). For this reason, impact of platelet and 
leukocyte recruitment on TNF-α expression as well as adipocyte biology and 
proliferation was tested. 
One of the most important questions remaining still incompletely addressed is the 
nature of the original TNF-α expression trigger in adipose tissue.  
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While obesity in rodents and humans is associated with an increase in apoptotic and 
necrotic adipocytes (237), it is also well known, that WAT expansion is associated 
with increased adipocyte death due to the limited capacity of adipocyte expansion.   
Proper immune function is closely linked to nutritional status, prompting the 
possibility that also the type of dietary components, like specific fats, may play a role 
in the regulation of adipocyte inflammation (126). 
Experiments described here showed no TNF-α expression after stimulation with ADP 
alone. Though ADP is an important factor for glucose utilization (205), respectively 
nutritional  status, its influence on adipocyte cytokine expression might not be that 
important when administered alone. 
PMA, representing a di-ester of phorbol and a potent tumor promoter, triggers the 
activation of Protein Kinase C (PKC). Although PKC is widely expressed in 
adipocytes as well as preadipocytes, stimulation via PMA does not effect TNF-α 
expression. It is more likely that PKC involved signaling pathways get activated via 
TNF-receptor 1 (TNFR1) after stimulation with TNF-α. Stimulation with Tyrodes, 
serving as negative control, revealed absolutely transparent results by not 
influencing the expression of TNF-α at all. 
TNF-α expression was detectable after adipocytes were treated with stimulated 
PMNs as well as unstimulated PMNs. Looking at the results it is striking, that the 
amount of expressed TNF-α is nearly identical in the PMNa and PMN group. A 
possible explanation for this observation could be a potential activation even of 
unstimulated PMNs due to time and temperature limitations. Therefore, results of 
PMNa and PMN were on similar levels. 
It seems that the pure presence of leukocytes in our setup influence the expression 
of TNF-α and that it makes no difference whether the leukocytes were previously 
activated or not.  
In obese patients, their grade of adiposity highly correlates with increased numbers 
of adipose tissue neutrophils, expressing neutrophil elastase (269) and significantly 
more hyperoxides than compared to lean individuals (34). Neutrophil elastase is 
closely linked to expression of cytokines, like TNF-α, as revealed from previous 
studies (9).  
Discussion  105 
 
Hyperoxides are involved in apoptosis of cells and therefore in the activation of 
macrophages, leading to a pro-inflammatory state in obesity. Hereby, neutrophils 
contribute to adipose tissue inflammation in the early stages of obesity and are likely 
linked to cytokines, like TNF-α. 
This was also confirmed by treating the cells with a combination of platelets and 
leukocytes. While treatment with platelets alone had no effect on the expression of 
TNF-α, combination with leukocytes restored the previous described effect of 
expression. It made no difference, whether the platelets were activated or not in our 
setup. However, the both combinations with platelets revealed slightly lower levels of 
TNF-α serum levels compared to PMNa and PMN single groups. This could be 
partially due to diminished reactivity of neutrophils after complex forming with 
platelets and an accompanied altered effect on adipocyte TNF-α expression 
behavior. But importantly, the pure presence of neutrophils (and probably their 
secreted compounds) was the limiting factor in the TNF-α ELISA setting. 
Furthermore, it has to be mentioned that in vivo cytokine action results from a 
complex interplay between networks of pro- and anti-inflammatory cytokines (258). It 
is therefore likely that a coordinate regulation of anti-inflammatory cytokines such as 
IL-10 may play a role in both TNF-α expression and action in vivo, difficult to transfer 
into an in vitro setting.  
 
2.5.2. Adipocyte proliferation evaluation 
 
The experiments done previously were targeted at the expression profiles of mature 
adipocytes after stimulation with various substances. However, during the progress 
of adipogenesis, the differentiation phase from preadipocytes to adipocytes in vitro 
as well as the approximately 14-day long maturation phase is a critical step in the 
development of adipose tissue (236). For this reason, it was a consistent step to 
treat the premature adipocytes in a comparable way like previously described and 
the proliferation behavior was checked. 
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The experiments showed, that the proliferation/maturation of adipocytes decreased 
after they were treated with activated leukocytes. The same was true for the co-
incubation with inactivated leukocytes. Previous studies revealed a potential role of 
leukocytes in the regulation of adipogenesis via Interleukin-17 (IL-17), also after 
stimulation with PMA as described in chapter II 4.6.3 (85, 151).  
The group treated with the supernatant of activated platelets showed a decrease in 
proliferation behavior as well. Activated platelets, mainly releasing soluble CD40, 
may contribute to adipogenesis. In humans a close link between soluble CD40 
Ligand (sCD40L) and BMI was found (246). This sCD40L is most likely to interact 
with CD40 found on adipocytes and stromal adipose fraction. After being activated, 
CD40 induces adipose cytokine secretion (199) and a dose dependent expression of 
inflammatory cytokines IL-6 and IL-8 (167), major regulators of adipose tissue 
metabolism. 
The group treated solely with activated platelets showed no effect on adipocyte 
proliferation. This may be due to the fact that leukocytes are able to interact with 
adipocytes directly after transmigration. Platelets are quite unlikely to be interacting 
with adipocytes, rather than interacting via paracrine effects. This paracrine effects 
can be detected in the platelet supernatant group but they lack in the setting 
described here and therefore have no influence on the proliferation behavior of 
adipocytes in vitro. 
The most prominent decrease of adipocyte proliferation was found in the groups 
treated with TNF-α. Being significantly reduced on mRNA levels in the fat pad of 
GPIIb deficient mice and on the other hand overexpressed after stimulation with 
diverse substances, TNF-α probably links cytokine expression in adipose tissue with 
adipocyte development and proliferation. The tumor necrosis factor receptors 
(TNFR) may not have catalytic activity itself; instead they can transmit signals by 
recruiting intracellular proteins (adapter-proteins). These adapter-proteins can 
interact with domains of cytoplasmic sections of the receptors to activate specific 
downstream signals.  
Several adapter complexes are linked to the death domain of tumor necrosis factor 
receptor 1 (TNFR1-DD) that has been closely linked to mediate many effects on 
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adipocyte biology (41, 60). TNFR1-DD is responsible for the cytotoxic signals 
induced by TNF-α, for example TNF-α induced cell death in adipocytes (201).  
 
TNFR1-DD is also linked to the activation of nuclear factor-kappa B (NFκB), 
activated by TNF-α, mediating metabolic dysregulation (113) and controlling cell 
proliferation (123, 216). Moreover, inhibition of NFκB has shown to lead to an 
increase in human adipogenesis (71).  
Interestingly, groups treated with a combination of activated platelets and leukocytes 
did not significantly chance the proliferation behavior of adipocytes. This setup was 
used to further investigate a potential role of platelet and leukocyte interaction in the 
development of obesity. However, the previous experiments focused on an 
interaction to facilitate migration of leukocytes to the adipose tissue. Since migration 
was not examined directly in this proliferation assays, it may be, that although 
leukocytes and activated platelets formed complexes, these complexes did not 
further affect the proliferation behavior of adipocytes in vitro. 
Co-incubation of tyrodes and ADP did not influence adipocyte differentiation or 
proliferation, as mentioned in literature (191) and it is also reflected in the here 
described experiments. Stimulation with tyrodes alone revealed absolutely 
transparent results by not influencing the proliferation behavior of adipocytes. Also 
stimulation with PMA mainly triggering activation of Protein Kinase C in adipocytes 
did not affect the proliferation behavior as described in literature (81), 
comprehensible also in the experiments performed here.  
 
2.6. TNF-α blockage via Infliximab  
 
To further dissect a potential link of reduced TNF-α production in a lean mouse 
model culminating in expansion of WAT, TNF-α was blocked in vivo and the fat pad 
weight was evaluated as described above. Infliximab (Remicade®) is a chimeric 
monoclonal antibody directed against soluble and membrane-bound TNF-α and has 
shown to have considerable anti-inflammatory effects even in a mouse model by 
successfully blocking TNF-α effects (64).  
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In this project, reactivity of Infliximab was confirmed by ELISA, showing significantly 
reduced serum TNF-α levels in animals that were treated with Infliximab once per 
week, over a period of 6 weeks.  
Infliximab provokes a significant weight gain in all of the treated animals. The weight 
gain was triggered by significant increased fat pad weight. All analyzed WAT depots 
showed enlargement, although not in a significant manner. 
These findings once more support the theory of a platelet dependent leukocyte 
migration to WAT in the pathogenesis of adipose tissue inflammation. In addition to 
the direct effect of Infliximab blocking TNF-α activity in WAT resulting in increased fat 
pad formation, there is also connection at another level:  
Already inhibition of ICAM-1; impairing leukocyte binding, adhesion and furthermore 
leukocyte transmigration into the tissue; leads to a significant WAT expansion in 
mice (69, 257). Same findings were also confirmed in mice with deficiency of the 
integrin αMβ2 (Mac-1), ICAM-1 counter receptor expressed on leukocytes (69). 
Increased WAT expansion was also found in TNF-α deficient animals after receiving 
HFD (210).  
Also in humans, treatment with Infliximab causes significant weight gain, for example 
in the treatment of Crohn’s disease (130) or Psoriasis (239).  
Taken together, the results described here support a role of TNF-α in adipose tissue 
biology. In similar fashion to TNF-α deficient animals, which have been reported to 
show significantly higher weight gain after HFD than wild type animals (210), direct 
blockade of TNF-α also leads to an increase of WAT formation, even after a 
treatment of 6 weeks. It is absolutely likely that TNF-α expression in adipose tissue 
leads to activation of NFκB, influencing adipocyte proliferation and adipogenesis. 
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3. Summary 
 
In conclusion a previously unknown role of platelets in the pathogenesis of obesity 
and homeostasis of body weight was identified by this work. Platelets chronically 
adhere to vessels of the inflamed adipose tissue and in this manner support 
leukocytes migrating into adipose tissue to regulate chronic inflammatory processes 
in the pathogenesis of obesity. The data supports the concept that impairment of 
immune cell accumulation in WAT allows for an increase in body fat and obesity.  
 
 
 
Figure 40: Model on adipocyte proliferation in GPIIb wild type animals 
In the presence of functional GPIIb integrin (grey) platelets (red) support leukocytes (neutrophils, blue) 
Discussion  110 
migrating into the adipose tissue and in this way regulate adipocyte proliferation via TNF-α (yellow).  
 
 
 
Platelet αIIbβ3 integrin mediates binding to the endothelial receptor ICAM-1 via 
adhesive bridging proteins like vWF. Adherent platelets facilitate leukocyte 
accumulation, partially by formation of platelet-leukocytes complexes. In addition, 
leukocytes get activated after interaction with platelets and migrate into the adipose 
tissue via intracellular adhesion molecules. Within the adipose tissue activated 
leukocytes seem to trigger the expression of TNF-α and might provoke release of 
further, so far unidentified pro-inflammatory cytokines, which transmit signals by 
recruiting intracellular adapter-proteins. These adapter-proteins might enable 
downstream signals, closely linked to the activation of NFκB. NFκB could probably 
control metabolic dysregulation, leading to inhibition of cell proliferation and a 
potential decrease of adipogenesis (Fig. 40). 
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Figure 41: Model on adipocyte proliferation in GPIIb Knockout animals 
In the absence of functional GPIIb integrin (grey) platelets (red) cannot support leukocytes 
(neutrophils, blue) migrating into the adipose tissue. In this way adipocyte proliferation is not 
influenced via TNF-α (yellow).  
 
 
 
With deficient αIIbβ3 integrin on platelets they cannot bind to the endothelium, at the 
same time interaction with leukocytes via platelet-leukocyte complexes is impaired. 
Less platelet adhesion to the endothelium in GPIIb deficient mice was confirmed by 
intravital microscopy. In addition, platelet interaction with leukocytes is down 
regulated, resulting in less migration of leukocytes into the adipose tissue, as 
confirmed by Immunohistological experiments. Moreover, expression of TNF-α and 
other pro-inflammatory cytokines is reduced as seen in mRNA analysis and in vitro 
assays. Activation and effect of NFκB might be reduced, leading to uncontrolled 
adipocyte proliferation and the increase of WAT formation (Fig. 41), as detected in 
the weight development of GPIIb-deficient animals compared to wild type mice. The 
same effect was also repeated after inhibiting the TNF-α expression in BL/6 mice 
using Infliximab, resulting in an increased weight gain even after 6-week treatment 
compared to vehicle treated mice. 
To this date a role of so far unidentified platelet-mediated effects on obesity may not 
be completely ruled out. It is from high priority to further examine exact platelet and 
leukocyte mechanisms during adipose tissue inflammation for a better understanding 
of normal body weight maintenance. 
Chronic inflammatory processes were identified in WAT during onset and promotion 
of obesity, with endothelial activation and transmigration of leukocytes after 
interaction with platelets during the initiation of weight gain. It can be concluded, that 
platelets regulate inflammatory processes of the adipose tissue, as shown in chronic 
platelet adhesion to adipose tissue vasculature, which seems to promote white blood 
cell recruitment to adipose tissue. 
Transgenic mice with malfunction in platelet adhesion showed decreased white 
blood cell accumulation in the WAT, resulting in significantly increased body fat 
mass. There is an essential role of platelets and leukocytes in chronic inflammatory 
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processes during initiation and development of obesity. 
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VIII. ABBREVIATION LIST 
3D:  three-dimensional 
A:  Arteria (lat.) 
AA:  Amino acid 
Aa:  Arteriae (lat.) 
Ab:  Antibody 
Abbr:  Abbreviation 
ADP:  Adenosindiphsophat 
ApoE:   Apolipoprotein E 
ATP:  Adenosintriphosphat 
BAT:  Brown adipose tissue 
BM:  Basal membrane 
Bm:  Bone marrow 
BSA:  Bovine serum albumin 
°C:  Degree Celsius 
CCL2:  Chemokine (C-C motif)  ligand 2 
CD:  Cluster of Differentiation 
Cm:  Centimeter 
CNS:  Central nervous system 
Co:  Company 
CXCL:  CXC chemokine ligand 
CXCR:  CXC chemokine receptor 
DAMPs: Damage associated molecular patterns 
DNA:  Desoxyribonucleinacid 
E.g.:  Exempli gratia 
eGFP: Enhanced green fluorescent protein 
F1:  Filial generation 1 
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F2:   Filial generation 2 
FACS: Fluorescence activated cell-sorting system 
FCS: Fetal calve serum 
f.i.:  For instance 
Fig:  Figure 
g:  Gramm 
GP:  Glycoprotein 
GFP:  Green fluorescent protein 
h:  Hour 
ICAM-1: Intracellular adhesion molecule-1 
ICAM-2: Intracellular adhesion molecule-2 
IL-1b: Interleukin 1 beta 
IL-4: Interleukin 4 
IL-6: Interleukin 6 
IL-8: Interleukin 8 
IL-10: Interleukin 10 
IL-11: Interleukin 11 
IL-13: Interleukin 13 
IL-17: Interleukin 17 
i.p.:  Intraperitoneal 
i.v.:  Intravenous 
IVC:  Individually ventilated cages 
kg:  Kilogram 
kDa:   Kilo Dalton 
KO:  knockout 
LDL:   Low density lipoprotein 
LPS:  Lipopolysaccharide  
M.:  Musculus (lat.) 
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m:  Meter 
Mac-1:  Macrophages-1 antigen 
min:  Minutes 
µg:  Microgram 
µl:  Microliter 
µM:  Micromolar 
µm:  Micrometer 
MMP:   Matrix metalloproteases 
  
ml:  Milliliter 
mm:  Millimeter 
mM:  Millimolar 
ms:  Millisecond 
nm:  Nanometer 
n:  Number 
NaCl:  Natrium chloride 
NE:  Neutrophil elastase 
NET:  Neutrophil extracellular traps 
NKC:  Natural killer cell 
PBS:  Phosphate Buffered Saline 
PCR:  Polymerase chain reaction 
PECAM: Platelet endothelial cell adhesion molecule  
 
PFA:  Paraformaldehyde 
pH: numeric scale to specify acidity of basicity of an aqueous solution 
Plt: Platelet 
PMN: Polymorphonuclear neutrophil 
PRP:  Platelet rich plasma 
PSGL-1: P-selectin glycoprotein  
ligand 1  
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rcf:  Relative centrifugal force 
resp.:  Respectively 
RNA:  Ribonucleic acid  
 
rpm:  Rounds per minute 
RT:  Room temperature 
s.:  Second 
s.c.:  Subcutan 
SD:  Standard deviation 
SEM:  Standard error of the mean 
Tab:  Table 
TNF-α:  Tumor necrosis factor α 
V:  Vena (lat.) 
VCAM-1: Vascular cell adhesion molecule-1 
VE-cadherine: Vascular endothelial-cadherin  
 
vs: Versus 
vWF:  Von Willebrand Factor 
WAT:  White adipose tissue 
wt:  wild type 
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